

Литература

1. Head SJ, Kieser TM, Falk V, et al. Coronary artery bypass grafting: Part 1: the evolution over the first 50 years. *Eur Heart J* 2013;34(37):2862–72.
2. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1978;1(8058):263.
3. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. *N Engl J Med* 2013;368(3):254–65.
4. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation vs. Medical Treatment in Patients With Stable Coronary Artery Disease: A Network Meta-Analysis. *BMJ*. 2014 Jun 23;348:g3859.
5. Head SJ, Kaul S, MackMJ, et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. *Eur Heart J* 2013;34(32):2510–8.
6. Head SJ, Holmes DR Jr., Mack MJ, et al. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. *JACC Cardiovasc Interv* 2012;5(6):618–25.
7. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). *Eur J Cardiothorac Surg* 1999;16(1):9–13.
8. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. *Eur Heart J* 2003;24(9):881–882.
9. Siregar S, Groenwold RH, de Heer F, Bots ML, van der Graaf Y, van Herwerden LA. Performance of the original EuroSCORE. *Eur J Cardiothorac Surg* 2012;41(4):746–54.
10. Hickey GL, Grant SW, Murphy GJ, et al. Dynamic trends in cardiac surgery: why the logistic EuroSCORE is no longer suitable for contemporary cardiac surgery and implications for future risk models. *Eur J Cardiothorac Surg* 2013;43(6):1146–52.
11. Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41(4):734–744; discussion 744–5.
12. Biancari F, Vasques F, Mikkola R, et al. Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery. *Ann Thorac Surg* 2012;93(6):1930–5.
13. Chalmers J, Pullan M, Fabri B, et al. Validation of EuroSCORE II in a modern cohort of patients undergoing cardiac surgery. *Eur J Cardiothorac Surg* 2013;43(4):688–94.
14. Grant SW, Hickey GL, Dimarakis I, et al. How does EuroSCORE II perform in UK cardiac surgery: an analysis of 23 740 patients from the Society for Cardiothoracic Surgery in Great Britain and Ireland National Database. *Heart* 2012;98(21):1568–72.
15. Shahian DM, O'Brien SM, Filardo G, et al. Society of Thoracic Surgeons Quality Measurement Task F. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3: valve plus coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88(1 Suppl):S43–62.
16. Shahian DM, O'Brien SM, Filardo G, et al. Society of Thoracic Surgeons Quality Measurement Task F. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1: coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88(1 Suppl):S2–22.
17. Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013;381(9867):629–38.
18. Mohr FW, Rastan AJ, SerruysPW, et al. Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. *J Thorac Cardiovasc Surg* 2011;141(1):130–40.
19. Genereux P, Palmerini T, Caixeta A, et al. SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. *Circ Cardiovasc Interv* 2011;4(6):553–61.
20. Papadopoulou SL, Girasis C, Dharampala A, et al. CT-SYNTAX score: a feasibility and reproducibility Study. *JACC Cardiovasc Imaging* 2013;6(3):413–5.
21. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. *J Am Coll Cardiol* 2010;55(18):1923–32.
22. Ranucci M, Castelvichio S, Menicanti L, et al. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. *Circulation* 2009;119(24):3053–61.
23. Wykrzykowska JJ, Garg S, Onuma Y, et al. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial. *Circ Cardiovasc Interv* 2011;4(1):47–56.
24. Farooq V, Vergouwe Y, Raber L, et al. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. *Eur Heart J* 2012;33(24):3098–104.
25. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet* 2013;381(9867):639–50.
26. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. *N Engl J Med* 2012;366(16):1467–76.
27. Shahian DM, O'Brien SM, Sheng S, et al. Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). *Circulation* 2012;125(12):1491–500.
28. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. *Circulation* 2012;125(12):1501–1510.
29. Medina A, Suarez de Lezo J, Pan M. [A new classification of coronary bifurcation lesions]. *Rev Esp Cardiol* 2006;59(2):183.
30. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention* 2005;1(2):219–27.
31. Beauchamp T, Childress J. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994.
32. Tong BC, Huber JC, Ascheim DD, et al. Weighting composite endpoints in clinical trials: essential evidence for the Heart Team. *Ann Thorac Surg* 2012;94(6):1908–13.
33. Chandrasekharan DP, Taggart DP. Informed consent for interventions in stable coronary artery disease: problems, etiologies, and solutions. *Eur J Cardiothorac Surg* 2011;39(6):912–7.
34. Filardo G, Maggioni AP, Mura G, et al. The consequences of under-use of coronary revascularization; results of a cohort study in Northern Italy. *Eur Heart J* 2001;22(8):654–62.
35. Yates MT, Soppa GK, Valencia O, et al. Impact of European Society of Cardiology and European Association for Cardiothoracic Surgery Guidelines on Myocardial Revascularization on the activity of percutaneous coronary intervention and coronary artery bypass graft surgery for stable coronary artery disease. *J Thorac Cardiovasc Surg* 2014;147(2):606–10.
36. OECD. Health at a glance. In: OECD Publishing; 2009.
37. Hannan EL, Cozzens K, Samadashvili Z, et al. Appropriateness of coronary revascularization for patients without acute coronary syndromes. *J Am Coll Cardiol* 2012;59(21):1870–6.
38. Frutkin AD, Lindsey JB, Mehta SK, et al. Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). *JACC Cardiovasc Interv* 2009;2(7):614–21.
39. Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001–2008. *JAMA* 2011;305(17):1769–76.
40. Hannan EL, Racz MJ, Gold J, et al. American College of C, American Heart A. Adherence of catheterization laboratory cardiologists to American College of Cardiology/American Heart Association guidelines for percutaneous coronary interventions and coronary artery bypass graft surgery: what happens in actual practice? *Circulation* 2010;121(2):267–75.
41. Denvir MA, Pell JP, Lee AJ, et al. Variations in clinical decision-making between cardiologists and cardiac surgeons: a case for management by multidisciplinary teams? *J Cardiothorac Surg* 2006;1:2.
42. Long J, Luckraz H, Thekkudan J, et al. Heart Team discussion in managing patients with coronary artery disease: outcome and reproducibility. *Interact Cardiovasc Thorac Surg* 2012;14(5):594–8.
43. Sobolev BG, Fradet G, Kuramoto L, Rogula B. The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population based observational study. *J Cardiothorac Surg* 2013;8:74.
44. Graham MM, Knudtson ML, O'Neill BJ, Ross DB. Treating the right patient at the right time: Access to cardiac catheterization, percutaneous coronary intervention and cardiac surgery. *Can J Cardiol* 2006;22(8):679–83.
45. Hannan EL, Samadashvili Z, Walford G, et al. Predictors and outcomes of ad hoc vs. non-ad hoc percutaneous coronary interventions. *JACC Cardiovasc Interv* 2009;2(4):350–6.
46. Nallamothu BK, Krumholz HM. Putting ad hoc PCI on pause. *JAMA* 2010;304(18):2059–2060.
47. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;34(38):2949–3003.
48. Knuuti J, Bengel F, Bax JJ, et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. *Eur Heart J* 2014;35(10):633–8.
49. Hulten E, Villines TC, Cheezum MK, et al. Usefulness of coronary computed tomography angiography to predict mortality and myocardial infarction among Caucasian, African and East Asian ethnicities (from the CONFIRM [Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter] Registry). *Am J Cardiol* 2013;111(4):479–85.
50. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve vs. angiography for guiding percutaneous coronary intervention. *N Engl J Med* 2009;360(3):213–24.
51. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol* 2007;49(21):2105–11.
52. Botman KJ, Pijls NH, Bech JW, et al. Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement. *Catheter Cardiovasc Interv* 2004;63(2):184–91.
53. Toth G, De Bruyne B, Casselman F, et al. Fractional flow reserve-guided vs. angiography-guided coronary artery bypass graft surgery. *Circulation* 2013;128(13):1405–11.
54. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI vs. medical therapy in stable coronary disease. *N Engl J Med* 2012;367(11):991–1001.

55. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. *J Am Coll Cardiol* 2002;39(7):1151–8.
56. Beanlands RS, Nichol G, Huszti E, et al. 18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). *J Am Coll Cardiol* 2007;50(20):2002–12.
57. Meijboom WB, Meijjs MF, Schuijff JD, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. *J Am Coll Cardiol* 2008;52(25):2135–44.
58. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. *N Engl J Med* 2008;359(22):2324–36.
59. Sarno G, Decraemer I, Vanhoenacker PK, et al. On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography. *JACC Cardiovasc Interv* 2009;2(6):550–7.
60. Schuijff JD, Wijns W, Jukema JW, et al. A comparative regional analysis of coronary atherosclerosis and calcium score on multislice CT vs. myocardial perfusion on SPECT. *J Nucl Med* 2006;47(11):1749–55.
61. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol* 2008;52(21):1724–32.
62. Neglia D, Rovai D, Caselli C, et al, For the EVINCI Investigators. Detection of obstructive coronary artery disease by non invasive anatomical and functional imaging. Results of the multicenter European EVINCI study. *Circulation* 2013.
63. Elhendy A, Shub C, McCully RB, et al. Exercise echocardiography for the prognostic stratification of patients with low pretest probability of coronary artery disease. *Am J Med* 2001;111(1):18–23.
64. Elhendy A, MahoneyDW, Burger KN, et al. Prognostic value of exercise echocardiography in patients with classic angina pectoris. *Am J Cardiol* 2004;94(5):559–63.
65. Sicari R, Pasanisi E, Venneri L, et al, Echo Persantine International Cooperative Study G, Echo Dobutamine International Cooperative Study G. Stress echo results predict mortality: a large-scale multicenter prospective international study. *J Am Coll Cardiol* 2003;41(4):589–95.
66. Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. *Circulation* 2002;105(1):32–40.
67. Mc Ardle BA, Dowsley TF, deKemp RA, et al. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: A systematic review and meta-analysis. *J Am Coll Cardiol* 2012;60(18):1828–37.
68. ShawLJ, Hendel R, Borges-Neto S, et al, Myoview Multicenter R. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. *J Nucl Med* 2003;44(2):134–9.
69. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. *J Nucl Med* 2006;47(1):24–33.
70. Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography vs. single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. *Circ Cardiovasc Imaging* 2012;5(6):700–7.
71. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. *J Am Coll Cardiol* 2007;50(14):1343–53.
72. Schwitler J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. *Eur Heart J* 2008;29(4):480–9.
73. Schwitler J, Wacker CM, Wilke N et al. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. singlephoton emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. *Eur Heart J* 2013;34(10):775–81.
74. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. *Circulation* 2007;115(13):1769–76.
75. Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: assessment of myocardial wall motion and perfusion. *J Am Coll Cardiol* 2010;56(15):1225–34.
76. Dorbala S, Di Carli MF, Beanlands RS, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. *J Am Coll Cardiol* 2013;61(2):176–84.
77. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. *Circulation* 2012;126(15):1858–68.
78. Kajander S, Joutsiniemi E, Saraste M, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. *Circulation* 2010;122(6):603–13.
79. Pazhenkottil AP, Nkoulou RN, Ghadri JR, et al. Impact of cardiac hybrid single-photon emission computed tomography/computed tomography imaging on choice of treatment strategy in coronary artery disease. *Eur Heart J* 2011;32(22):2824–9.
80. Danad I, Rajmakers PG, Appelman YE, et al. Hybrid imaging using quantitative H215O PET and CT-based coronary angiography for the detection of coronary artery disease. *J Nucl Med* 2013;54(1):55–63.
81. Schaap J, de Groot JA, Nieman K, et al. Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions. *Heart* 2013;99(3):188–94.
82. Fiechter M, Ghadri JR, Wolfrum M, et al. Downstream resource utilization following hybrid cardiac imaging with an integrated cadmium-zinc-telluride/64-slice CT device. *Eur J Nucl Med Mol Imaging* 2012; 39(3):430–6.
83. van Werkhoven JM, Heijnenbroek MW, Schuijff JD, et al. Combined non-invasive anatomical and functional assessment with MSCT and MRI for the detection of significant coronary artery disease in patients with an intermediate pre-test likelihood. *Heart* 2010;96(6):425–31.
84. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013;34(39):3035–87.
85. Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. *Eur J Cardiothorac Surg* 2010;38 Suppl:S1–S52.
86. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2010;31(20):2501–55.
87. Deb S, Wijesundera HC, Ko DT, et al. Coronary artery bypass graft surgery vs. percutaneous interventions in coronary revascularization: a systematic review. *JAMA* 2013;310(19):2086–95.
88. Spertus JA, Salisbury AC, Jones PG, et al. Predictors of quality-of-life benefit after percutaneous coronary intervention. *Circulation* 2004;110(25):3789–94.
89. Coronary angioplasty vs. medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet* 1997;350(9076):461–468.
90. Trial of invasive vs. medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. *Lancet* 2001;358(9286):951–7.
91. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356(15):1503–16.
92. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. *JAMA* 2007;297(18):1985–91.
93. Frye RL, August P, BrooksMM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360(24):2503–15.
94. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* 2010;122(10):949–57.
95. Wijesundera HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: effects of percutaneous coronary intervention vs. medical therapy on angina relief. *Ann Intern Med* 2010;152(6):370–9.
96. Pursnani S, Korley F, Gopal R, et al. Percutaneous coronary intervention vs. optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. *Circ Cardiovasc Interv* 2012;5(4):476–90.
97. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *Eur Heart J* 2011;32(8):1012–24.
98. Sajadieh A, NielsenOW, Rasmussen V, et al. Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. *Eur Heart J* 2005;26(14):1402–9.
99. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation* 2008;117(10):1283–91.
100. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials. *JAMA Intern Med* 2014;174(2):232–40.
101. Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical

- Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. *J Am Coll Cardiol* 2011;58(8):849–60.
102. Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. *J Am Coll Cardiol* 2007;50(12):1161–70.
 103. Califf RM, Armstrong PW, Carver JR, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. *J Am Coll Cardiol* 1996;27(5):1007–19.
 104. Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. *Circ Cardiovasc Interv* 2008;1(1):10–9.
 105. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention vs. optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. *Circulation* 2013;127(7):769–81.
 106. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;373(9670):1190–7.
 107. Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. *Am J Med* 2009;122(2):152–61.
 108. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet* 1994;344(8922):563–70.
 109. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. *Lancet* 1982;2(8309):1173–80.
 110. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. *N Engl J Med* 1984;311(21):1333–9.
 111. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. *N Engl J Med* 1984;310(12):750–58.
 112. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011;364(17):1607–16.
 113. Pitt B, Waters D, Brown WW, van Boven AJ, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin vs. Revascularization Treatment Investigators. *N Engl J Med* 1999;341(2):70–6.
 114. Zeymer U, Uebis R, Vogt A, et al. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. *Circulation* 2003;108(11):1324–8.
 115. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med* 2006;355(23):2395–407.
 116. Nishigaki K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: a randomized, comparative, multicenter study. *JACC Cardiovasc Interv* 2008;1(5):469–79.
 117. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty vs. medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. *BMJ* 2000;321(7253):73–7.
 118. Kastritis DG, Ioannidis JP. Percutaneous coronary intervention vs. conservative therapy in nonacute coronary artery disease: a meta-analysis. *Circulation* 2005;111(22):2906–12.
 119. Schomig A, Mehilli J, deWaha A, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. *J Am Coll Cardiol* 2008;52(11):894–904.
 120. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. *Lancet* 2009;373(9667):911–8.
 121. Hannan EL, Samadashvili Z, Cozzens K, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. *Circulation* 2012;125(15):1870–9.
 122. Shaw LJ, Weintraub WS, Maron DJ, et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. *Am Heart J* 2012;164(2):243–50.
 123. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs. medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. *Arch Intern Med* 2012;172(4):312–9.
 124. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet* 2007;370(9591):937–48.
 125. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. *Circulation* 2012;125(23):2873–91.
 126. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). *JACC Cardiovasc Interv* 2013;6(9):914–22.
 127. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. *J Am Coll Cardiol* 2011;58(15):1569–77.
 128. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 2012; 33(10):1214–22.
 129. Stefanini GG, Baber U, Windecker S, et al. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomized trials. *Lancet* 2013;382(9908):1879–88.
 130. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents vs. durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. *Lancet* 2011;378(9807):1940–8.
 131. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. *Lancet* 2012;379(9824):1393–402.
 132. Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. *BMJ* 2013;347:f6625.
 133. Kaiser C, Galatius S, Erne P, et al. Drug-eluting vs. bare-metal stents in large coronary arteries. *N Engl J Med* 2010;363(24):2310–9.
 134. Bittl JA, He Y, Jacobs AK, et al. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. *Circulation* 2013;127(22):2177–85.
 135. Dzavik V, GhalilWA, Norris C, et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. *Am Heart J* 2001;142(1):119–26.
 136. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. *Ann Thorac Surg* 2006;82(4):1420–1428; discussion 1428–9.
 137. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med* 2008;358(4):331–341.
 138. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. *Circulation* 1995;91(9):2335–44.
 139. Chaitman BR, Hardison RM, Adler D, et al. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation* 2009;120(25):2529–40.
 140. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. *N Engl J Med* 1985;312(26):1665–71.
 141. Jones RH, Kesler K, Phillips HR 3rd, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. *J Thorac Cardiovasc Surg* 1996;111(5):1013–25.
 142. Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. *JAMA* 1994;272(19):1528–34.
 143. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation* 2003;107(23):2900–7.
 144. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy vs. revascularization. *Circulation* 1997;95(8):2037–43.
 145. Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. *Can J Cardiol* 2013;29(4):472–82.
 146. Coronary angioplasty vs. coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. *Lancet* 1993;341(8845):573–80.
 147. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med* 1994;331(16):1037–43.
 148. King SB 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty vs. Surgery Trial (EAST). *N Engl J Med* 1994;331(16):1044–50.
 149. First-year results of CABRI (Coronary Angioplasty vs. Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet* 1995;346(8984):1179–84.
 150. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med* 1996;335(4):217–25.

151. Morrison DA, Sethi G, Sacks J, et al. Angina With Extremely Serious Operative Mortality E. Percutaneous coronary intervention vs. coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). *J Am Coll Cardiol* 2001;38(1):143–9.
152. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting vs. Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. *J Am Coll Cardiol* 2001;37(1):51–8.
153. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med* 2001;344(15):1117–24.
154. Coronary artery bypass surgery vs. percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet* 2002;360(9338):965–70.
155. Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. *Circulation* 2003;108(23):2870–6.
156. Thiele H, Oetzel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. *Circulation* 2005;112(22):3445–50.
157. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention vs. coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360(10):961–72.
158. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents vs. coronary artery bypass grafting in unprotected left main stem stenosis. *J Am Coll Cardiol* 2011;57(5):538–45.
159. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents vs. bypass surgery for left main coronary artery disease. *N Engl J Med* 2011;364(18):1718–27.
160. Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. *JACC Cardiovasc Interv* 2008;1(5):483–91.
161. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass vs. percutaneous revascularization for isolated lesions of the left anterior descending artery. *BMJ* 2007;334(7594):617.
162. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. *N Engl J Med* 1986;314(1):1–6.
163. Cameron A, Davis KB, Green GE, et al. Clinical implications of internal mammary artery bypass grafts: the Coronary Artery Surgery Study experience. *Circulation* 1988;77(4):815–19.
164. Lytle BW, Blackstone EH, Sabik JF, et al. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. *Ann Thorac Surg* 2004;78(6):2005–2012; discussion 2012–2014.
165. Kurlansky PA, Traad EA, Dorman MJ et al. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. *Ann Thorac Surg* 2010;90(1):101–8.
166. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. *J Am Coll Cardiol* 2008;51(9):885–92.
167. Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- vs. sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009;53(19):1760–8.
168. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation* 2010;121(24):2645–53.
169. Morice MC, Serruys PW, Kappetein AP, et al. Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the SYNTAX Trial. *Circulation* 2014;129:2388–94.
170. Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary intervention vs. coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. *J Am Coll Cardiol* 2011;58(14):1426–32.
171. Buszman PE, Buszman PP, Kiesz RS, et al. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. *J Am Coll Cardiol* 2009;54(16):1500–11.
172. Park DW, Kim YH, Yun SC, et al. Long-term outcomes after stenting vs. coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. *J Am Coll Cardiol* 2010;56(17):1366–75.
173. Sipahi I, Akay MH, Dagdelen S, et al. Coronary Artery Bypass Grafting vs. Percutaneous Coronary Intervention and Long-term Mortality and Morbidity in Multivessel Disease: Meta-analysis of Randomized Clinical Trials of the Arterial Grafting and Stenting Era. *JAMA Intern Med* 2014;174(2):223–30.
174. Bravata DM, Gienger AL, McDonald KM, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. *Ann Intern Med* 2007;147(10):703–16.
175. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;367(25):2375–84.
176. Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. *Eur Heart J*. Published online 21 May 2014; doi: 10.1093/eurheartj/ehu213.
177. Wu C, Camacho FT, Zhao S, et al. Long-term mortality of coronary artery bypass graft surgery and stenting with drug-eluting stents. *Ann Thorac Surg* 2013;95(4):1297–305.
178. Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. *JACC Cardiovasc Interv* 2013;6(1):20–26.
179. Thiele H, Neumann-Schriedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery vs. sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. *J Am Coll Cardiol* 2009;53(25):2324–31.
180. Hamm CW, Bassand JP, Agewall S, et al. Guidelines ESCCfP. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32(23):2999–3054.
181. Mehta SR, Cannon CP, Fox KA, et al. Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA* 2005;293(23):2908–17.
182. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. *J Am Coll Cardiol* 2006;48(7):1319–25.
183. O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs. conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA* 2008;300(1):71–80.
184. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine vs. selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. *J Am Coll Cardiol* 2010;55(22):2435–45.
185. Katritsis DG, Siontis GC, Kastrati A, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. *Eur Heart J* 2011;32(1):32–40.
186. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. *Ann Intern Med* 2013;158(4):261–70.
187. Mehta SR, Granger CB, Boden WE, et al. Early vs. delayed invasive intervention in acute coronary syndromes. *N Engl J Med* 2009;360(21):2165–75.
188. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J* 2007;28(14):1709–16.
189. Ben-Gal Y, Moses JW, Mehran R, et al. Surgical vs. percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *JACC Cardiovasc Interv* 2010;3(10):1059–67.
190. Palmerini T, Genereux P, Caixeta A, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *J Am Coll Cardiol* 2011;57(24):2389–97.
191. Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. *Am Heart J* 2008;155(1):140–6.
192. Hannan EL, Samadashvili Z, Walford G, et al. Staged vs. one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction. *Circ Cardiovasc Interv* 2013;6(1):12–20.
193. Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Circulation* 2012;125(21):2613–20.
194. Monteiro P. Impact of early coronary artery bypass graft in an unselected acute coronary syndrome patient population. *Circulation* 2006;114(1 Suppl):I467–I472.
195. Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). *JACC Cardiovasc Interv* 2010;3(4):419–27.
196. Greenhalgh J, Hockenfull J, Rao N, et al. Drug-eluting stents vs. bare metal stents for angina or acute coronary syndromes. *Cochrane Database Syst Rev* 2010(5):CD004587.
197. Amsterdam EA, Kirk JD, Diercks DB, et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. *J Am Coll Cardiol* 2002;40(2):251–6.
198. Nyman I, Wallentin L, Areskog M, et al. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. *Int J Cardiol* 1993;39(2):131–42.

199. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. *Circulation* 2009;119(25):3198–206.
200. Moses JW, Mehran R, Nikolov E, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. *J Am Coll Cardiol* 2005;45(8):1165–71.
201. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33(20):2569–619.
202. Gershlick AH, Banning AP, Myat A, et al. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? *Lancet* 2013;382(9892):624–32.
203. Miedema MD, Newell MC, Duval S, et al. Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction. *Circulation* 2011;124(15):1636–44.
204. Herrin J, Miller LE, Turkmani DF, et al. National performance on door-in to door-out time among patients transferred for primary percutaneous coronary intervention. *Arch Intern Med* 2011;171(21):1879–86.
205. Wang TY, Nallamothu BK, Krumholz HM, et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. *JAMA* 2011;305(24):2540–7.
206. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127(4):e362–e425.
207. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *Lancet* 1996;348(9030):771–5.
208. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 2006;27(7):779–88.
209. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. *Lancet* 2006;367(9510):579–88.
210. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty vs. prehospital fibrinolysis in acute myocardial infarction: a randomized study. *Lancet* 2002;360(9336):825–9.
211. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. *Eur Heart J* 2009;30(13):1598–606.
212. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. *JAMA* 2000;283(20):2686–92.
213. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation* 2003;108(23):2851–6.
214. Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation* 2011;124(23):2512–21.
215. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med* 2013;368(15):1379–87.
216. Bates ER, Jacobs AK. Time to treatment in patients with STEMI. *N Engl J Med* 2013;369(10):889–92.
217. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. *JAMA* 2000;284(1):60–7.
218. Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. *Eur Heart J* 2014;35:1957–70.
219. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003;349(8):733–42.
220. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty vs. immediate thrombolysis in acute myocardial infarction: a meta-analysis. *Circulation* 2003;108(15):1809–14.
221. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med* 1999;341(9):625–34.
222. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. *Circulation* 2009;119(14):1933–40.
223. Busk M, Kalltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for >12 h vs. 12–72 h. *Eur Heart J* 2009;30(11):1322–30.
224. Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA* 2005;293(23):2865–72.
225. Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). *Circulation* 2006;113(20):2398–405.
226. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. *Circulation* 2007;116(7):721–8.
227. Nallamothu BK, Krumholz HM, Ko DT, et al. Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications. *Circulation* 2007;116(2):e68–e72.
228. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *Eur Heart J* 2010;31(8):943–57.
229. Knot J, Widimsky P, Wijns W, et al. How to set up an effective national primary angioplasty network: lessons learned from five European countries. *EuroIntervention* 2009;5(3):299, 301–9.
230. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med* 2006;355(22):2308–20.
231. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. *Circulation* 2006;114(19):2019–25.
232. Steg PG, Cambou JP, Goldstein P, et al. Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registry. *Heart* 2006;92(10):1378–83.
233. Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). *Am J Cardiol* 2009;104(4):507–13.
234. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged vs. “one-time” multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *J Am Coll Cardiol* 2011;58(7):704–11.
235. Politi L, Sgura F, Rossi R, et al. A randomized trial of target-vessel vs. multi-vessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during longterm follow-up. *Heart* 2010;96(9):662–7.
236. Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomized HEPacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent* 2004;6(3–4):128–33.
237. Jolly SS, Yusuf S, Cairns J, et al. Radial vs. femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet* 2011;377(9775):1409–20.
238. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial vs. femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Vs. Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. *J Am Coll Cardiol* 2012;60(24):2481–9.
239. Baklanov DV, Kaltenbach LA, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). *J Am Coll Cardiol* 2013;61(4):420–6.
240. Hamon M, Pripstino C, Di Mario C, et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. *EuroIntervention* 2013;8(11):1242–51.
241. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting vs. balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. *Am J Med* 2004;116(4):253–62.
242. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346(13):957–66.
243. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor vs. bivalirudin monotherapy and paclitaxel-eluting stents vs. bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomized controlled trial. *Lancet* 2011;377(9784):2193–204.
244. Kalesan B, Pilgrim T, Heinemann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. *Eur Heart J* 2012;33(8):977–87.
245. Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. *J Am Coll Cardiol* 2011;57(4):390–8.
246. Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents vs. first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. *J Am Coll Cardiol* 2012;60(5):381–7.
247. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent vs. bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. *Lancet* 2012;380(9852):1482–90.

248. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs. bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. *JAMA* 2012;308(8):777–87.
249. Sabate M, Raber L, Heg D, et al. Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Pooled Analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArct-TION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) Trials. *JACC Cardiovasc Interv* 2014;7(1):55–63.
250. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet* 2008;371(9628):1915–20.
251. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. *J Am Coll Cardiol* 2009;53(4):309–15.
252. De Luca G, Dudek D, Sardella G, et al. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. *Eur Heart J* 2008;29(24):3002–10.
253. Costopoulos C, Gorog DA, Di Mario C, Kukreja N. Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. *Int J Cardiol* 2013;163(3):229–41.
254. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. *Int J Cardiol* 2013;166(3):606–12.
255. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. *Eur Heart J* 2008;29(24):2989–3001.
256. Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 2013;369(17):1587–97.
257. Ali A, Cox D, Dib N, Brodie B, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. *J Am Coll Cardiol* 2006;48(2):244–52.
258. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of Angio-Jet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. *J Am Coll Cardiol* 2010;56(16):1298–306.
259. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005;293(9):1063–72.
260. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet* 2010;375(9716):727–34.
261. Ibanez B, Macaya C, Sanchez-Brunete V et al. Effect of Early Metoprolol on Infarct Size in ST-Segment-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial. *Circulation* 2013;128(14):1495–503.
262. vanWerkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. *J Am Coll Cardiol* 2009;53(16):1399–409.
263. Stone GW, Abizaid A, Silber S, et al. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. *J Am Coll Cardiol* 2012;60:1975–84.
264. Hannan EL, Samadashvili Z, Walford G et al. Culprit vessel percutaneous coronary intervention vs. multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. *JACC Cardiovasc Interv* 2010;3(1):22–31.
265. Toma M, Buller CE, Westerhout CM, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. *Eur Heart J* 2010;31(14):1701–7.
266. Vlaar PJ, Mahmoud KD, Holmes DR Jr., et al. Culprit vessel only vs. multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. *J Am Coll Cardiol* 2011;58(7):692–703.
267. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. *N Engl J Med* 2013;369(12):1115–23.
268. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. *J Am Coll Cardiol* 2013;62(6):496–504.
269. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. *Eur Heart J* 2007;28(22):2706–13.
270. Karrowni W, Vyas A, Giacomino B, et al. Radial vs. femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. *JACC Cardiovasc Interv* 2013;6(8):814–23.
271. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. *N Engl J Med* 2008;358(21):2205–17.
272. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. *N Engl J Med* 2009;360(26):2705–18.
273. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty vs. standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REtEplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. *Lancet* 2008;371(9612):559–68.
274. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty vs. ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of theNORDISTEMI (NORwegian study on District treatment of ST-elevation myocardial infarction). *J Am Coll Cardiol* 2010;55(2):102–10.
275. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis vs. ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. *Lancet* 2004;364(9439):1045–53.
276. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention vs. thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). *J Am Coll Cardiol* 2005;46(3):417–24.
277. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. *J Am Coll Cardiol* 2003;42(4):634–41.
278. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. *Eur Heart J* 2010;31(17):2156–69.
279. Collet JP, Montalescot G, Le May M, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. *J Am Coll Cardiol* 2006;48(7):1326–35.
280. D'Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angioplasty vs. ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. *Eur Heart J* 2011;32(8):972–82.
281. Desch S, Eitel I, Rahimi K, deWaha S, et al. Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction: a meta-analysis of immediate or early routine vs. deferred or ischemia-guided randomised controlled trials. *Heart* 2010;96(21):1695–702.
282. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 2005;353(26):2758–68.
283. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA* 2001;285(2):190–92.
284. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. *Circulation* 1994;90(5):2280–4.
285. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011;124(23):e652–e735.
286. Weiss ES, Chang DD, Joyce DL, et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. *J Thorac Cardiovasc Surg* 2008;135(3):503–11, 511 e1–e3.
287. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;33(14):1787–847.
288. Velazquez EJ, Williams JB, Yow E, et al. Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting vs. medical therapy. *Ann Thorac Surg* 2012;93(2):523–30.
289. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med* 2011;364(17):1617–25.
290. Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia vs. hibernating myocardium. *Circ Cardiovasc Imaging* 2013;6(3):363–72.
291. Di Donato M, Castelvichio S, Menicanti L. End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy. *Eur J Heart Fail* 2010;12(4):375–81.
292. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. *N Engl J Med* 2009;360(17):1705–17.
293. Oh JK, Velazquez EJ, Menicanti L, et al. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. *Eur Heart J* 2013;34(1):39–47.
294. Michler RE, Rouleau JL, Al-Khalidi HR, et al. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. *J Thorac Cardiovasc Surg* 2013;146(5):1139–45 e6.
295. Dor V, Civaia F, Alexandrescu C, et al. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg* 2011;141(4):905–916, 916 e1–e4.

296. Lindholm MG, Kober L, Boesgaard S, et al. Trandolapril Cardiac Evaluation study g. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. *Eur Heart J* 2003;24(3):258–65.
297. Katz JN, Stebbins AL, Alexander JH et al. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acutemyocardial infarction despite a patent infarct artery. *Am Heart J* 2009;158(4):680–7.
298. Zeymer U, Vogt A, Zahn R, et al. Arbeitsgemeinschaft Leitende Kardiologische K. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Eur Heart J* 2004;25(4):322–28.
299. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. *Eur Heart J* 2003;24(9):828–37.
300. Kantrowitz A, Tjonneland S, Freed PS, et al. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. *JAMA* 1968;203(2):113–8.
301. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 2012;367(14):1287–96.
302. Thiele H, Zeymer U, Neumann FJ, et al Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. *Lancet* 2013;382(9905):1638–45.
303. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device vs. conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J* 2006;152(3):469 e1–e8.
304. Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic shock: interventional bridge to recovery. *Circulation* 2012;125(14):1809–17.
305. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J* 2005;26(13):1276–83.
306. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device vs. intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 2008;52(19):1584–8.
307. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. *Eur Heart J* 2009;30(17):2102–8.
308. Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. *J Heart Lung Transplant* 2012;31(2):117–26.
309. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. *J Heart Lung Transplant* 2013;32(2):141–56.
310. Kirklin JK, Naftel DC, Pagani FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? *J Thorac Cardiovasc Surg* 2012;144(3):584–603; discussion 597–8.
311. Cohn JN, Guha NH, Broder MI, Limas CJ. Right ventricular infarction. Clinical and hemodynamic features. *Am J Cardiol* 1974;33(2):209–14.
312. Dell'Italia LJ, Starling MR, Crawford MH, et al. Right ventricular infarction: identification by hemodynamic measurements before after volume loading correlation with noninvasive techniques. *J Am Coll Cardiol* 1984;4(5):931–9.
313. Goldstein JA. Pathophysiology and management of right heart ischemia. *J Am Coll Cardiol* 2002;40(5):841–853.
314. Goldstein JA, Barzilai B, Rosamond TL, et al. Determinants of hemodynamic compromise with severe right ventricular infarction. *Circulation* 1990;82(2):359–68.
315. Lorell B, Leinbach RC, Pohost GM, et al. Right ventricular infarction. Clinical diagnosis and differentiation from cardiac tamponade and pericardial constriction. *Am J Cardiol* 1979;43(3):465–71.
316. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. *J Am Coll Cardiol* 2003;41(8):1273–9.
317. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? *J Am Coll Cardiol* 2000;36(3 Suppl A):1063–70.
318. Brodie BR, Stuckey TD, Hansen C, et al. Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction vs. left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. *Am J Cardiol* 2007;99(4):431–435.
319. Zeymer U, Neuhaus KL, Wegscheider K, et al. Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis. *J Am Coll Cardiol* 1998;32(4):876–81.
320. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. *N Engl J Med* 1993;329(22):1615–22.
321. Kinn JW, O'Neill WW, Benzuly KH, et al. Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. *Cathet Cardiovasc Diagn* 1997;42(2):151–7.
322. Moreno R, Lopez-Sendon J, Garcia E, et al. Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. *J Am Coll Cardiol* 2002;39(4):598–603.
323. Menon V, Webb JG, Hillis LD, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries in cardiogenic shock? *J Am Coll Cardiol* 2000;36(3 Suppl A):1110–6.
324. Thiele H, Kaufersch C, Daehner I, et al. Immediate primary transcatheter closure of postinfarction ventricular septal defects. *Eur Heart J* 2009;30(1):81–8.
325. Zhu XY, Qin YW, Han YL, et al. Long-term efficacy of transcatheter closure of ventricular septal defect in combination with percutaneous coronary intervention in patients with ventricular septal defect complicating acute myocardial infarction: a multicenter study. *EuroIntervention* 2013;8(11):1270–6.
326. Assenza GE, McElhinney DB, Valente AM, et al. Transcatheter closure of post-myocardial infarction ventricular septal rupture. *Circ Cardiovasc Interv* 2013;6(1):59–67.
327. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? *J Am Coll Cardiol* 2000;36(3 Suppl A):1117–22.
328. Lopez-Sendon J, Gonzalez A, Lopez de Sa E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. *J Am Coll Cardiol* 1992;19(6):1145–53.
329. Menon V, Hochman JS, Stebbins A, et al. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. *Eur Heart J* 2000;21(23):1928–36.
330. Chevalier P, Burri H, Fahrat F, et al. Perioperative outcome and long-term survival of surgery for acute postinfarction mitral regurgitation. *Eur J Cardiothorac Surg* 2004;26(2):330–5.
331. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA* 2006;295(21):2511–15.
332. Sjauw KD, Engstrom AE, VisMM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? *Eur Heart J* 2009;30(4):459–68.
333. Buerke M, Prondzinsky R, Lemm H, et al. Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock: review of the current evidence. *Artif Organs* 2012;36(6):505–11.
334. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360(24):2503–15.
335. Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Journal of Nuclear Cardiology* 2012;19(4):658–69.
336. Brooks MM, Chaitman BR, Nesto RW, et al. Clinical, angiographic risk stratification differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation* 2012;126(17):2115–24.
337. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. *Circulation* 2008;118(16):1626–36.
338. O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. *J Am Coll Cardiol* 2012;60(2):106–11.
339. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 2000;102(9):1014–9.
340. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux vs. enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. *J Am Coll Cardiol* 2007;50(18):1742–51.
341. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361(11):1045–57.
342. Lagerqvist B, Husted S, Kontny F, et al. Fast Revascularisation during InStability in Coronary artery disease I. 5-year outcomes in the FRISC-II randomised trial of an invasive vs. a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. *Lancet* 2006;368(9540):998–1004.
343. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive vs. Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive vs. selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol* 2010;55(9):858–64.
344. Abdallah MS, Wang K, Magnuson EA, et al. Quality of life after PCI vs. CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. *JAMA* 2013;310(15):1581–90.
345. Serruys PW, Farooq V. Revascularization strategies in patients with diabetes. *N Engl J Med* 2013;368(15):1454–1455.
346. Kappetein AP, Head SJ, Morice MC et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery

- and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg* 2013;43(5):1006–13.
347. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010;55(5):432–40.
348. Kamalesh M, Sharp TG, Tang XC, et al. Percutaneous coronary intervention vs. coronary bypass surgery in United States veterans with diabetes. *J Am Coll Cardiol* 2013;61(8):808–16.
349. Verma S, Farkouh ME, Yanagawa B, et al. Comparison of coronary artery bypass surgery and percutaneous coronary interventions in patients with diabetes: a meta-analysis of randomized controlled trials. *Lancet Diabetes & Endocrinology* 2013;1(4):317–28.
350. Hakeem A, Garg N, Bhatti S, et al. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. *J Am Heart Assoc* 2013;2(4):e000354.
351. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. *BMJ* 2008;337:a1331.
352. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. *BMJ* 2012;345:e5170.
353. TaggartDP, Altman DG, Gray AM, et al. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). *Eur Heart J* 2010;31(20):2470–81.
354. Puskas JD, Sadiq A, Vassiliades TA, et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. *Annals of Thoracic Surgery* 2012;94(3):710–5;discussion 715–6.
355. Locker C, Schaff HV, Dearani JA, et al. Multiple arterial grafts improve late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease. *Circulation* 2012;126(9):1023–30.
356. Schwann TA, Al-Shaar L, Engoren M, Habib RH. Late effects of radial artery vs.saphenous vein grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis. *Eur J Cardiothorac Surg* 2013;44(4):701–10.
357. Giugliano RP, White JA, Bode C, et al. Early vs. delayed, provisional eptifibatid in acute coronary syndromes. *N Engl J Med* 2009;360(21):2176–90.
358. Mellbin LG, Malmberg K, Norhammar A, et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *Eur Heart J* 2008;29(2):166–76.
359. Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. *The Journal of Clinical Endocrinology and Metabolism* 2010;95(11):4993–5002.
360. Takagi T, Okura H, Kobayashi Y, et al. Aprospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). *JACC Cardiovascular Interventions* 2009;2(6):524–31.
361. Bhamidipati CM, LaPar DJ, Stukenborg GJ, et al. Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2011;141(2):543–51.
362. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;369(14):1317–26.
363. Timmer JR, Ottervanger JP, de Boer MJ, et al. Primary Coronary Angioplasty vs. Thrombolysis-2 Trialists Collaborators G. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs. Thrombolysis-2 trial. *Arch Intern Med* 2007;167(13):1353–9.
364. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med* 2001;344(25):1879–87.
365. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2004;25(3):190–8.
366. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. *Fragmin during Instability in Coronary Artery Disease*. *N Engl J Med* 2000;343(16):1139–47.
367. Lima EG, Hueb W, Garcia RM, et al. Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. *Am Heart J* 2013;166(2):250–7.
368. Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year followup of propensity score-matched cohorts. *Circulation* 2012;126(25):2935–42.
369. Chertow GM, Normand SL, McNeil BJ. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. *J Am Soc Nephrol* 2004;15(9):2462–8.
370. Charytan D, Mauri L, Agarwal A, et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. *Am Heart J* 2006;152(3):558–64.
371. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). *Circulation* 2009;120(10):851–8.
372. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. *Circulation* 2004;110(14):1890–5.
373. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. *J Am Soc Nephrol* 2003;14(9):2373–80.
374. Huang HD, Alam M, Hamzeh I, et al. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. *Int J Cardiol* 2013;168(4):3741–6.
375. Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. *J Am Coll Cardiol* 2011;58(18):1859–69.
376. Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. *PLoS One* 2010;5(11):e15070.
377. Ashrith G, LeeV, ElaydaMA, ReulRM, Wilson JM. Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. *Am J Cardiol* 2010;106(3):348–53.
378. Charytan DM, Li S, Liu J, Herzog CA. Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. *Circulation* 2012;126(11 Suppl 1):S164–9.
379. Ix JH, Mercado N, Shlipak MG, Lemos PA, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). *Am Heart J* 2005;149(3):512–9.
380. Chawla LS, Zhao Y, Lough FC, et al. Off-pump vs. on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. *J Am Soc Nephrol* 2012;23(8):1389–97.
381. Charytan DM, Yang SS, McGurk S, Rawn J. Long and short-term outcomes following coronary artery bypass grafting in patients with and without chronic kidney disease. *Nephrol Dial Transplant* 2010;25(11):3654–63.
382. Chang TI, Shilane D, Kazi DS, et al. Multivessel coronary artery bypass grafting vs. percutaneous coronary intervention in ESRD. *J Am Soc Nephrol* 2012;23(12):2042–9.
383. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. *Circulation* 2004;109(23):2866–71.
384. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs. sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA* 2008;300(9):1038–46.
385. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA* 2004;291(19):2328–34.
386. Li Y, Liu Y, Fu L, et al. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. *PLoS One* 2012;7(4):e34450.
387. Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. *J Am Coll Cardiol* 2013;62(23):2167–75.
388. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. *Ann Intern Med* 2009;150(3):170–7.
389. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. *J Am Coll Cardiol* 2007;50(7):584–90.
390. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010;121(3):357–65.
391. Yan LQ, Guo LJ, Zhang FC, Gao W. The relationship between kidney function and angiographically-derived SYNTAX score. *Can J Cardiol* 2011;27(6):768–72.
392. Zheng H, Xue S, Lian F, et al. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. *Eur J Cardiothorac Surg* 2013;43(3):459–67.
393. Del Duca D, Iqbal S, Rahme E, et al. Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. *Ann Thorac Surg* 2007;84(4):1264–71.
394. Ranucci M, Ballotta A, Kunkl A, et al. Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. *Am J Cardiol* 2008;101(8):1112–8.
395. Medalion B, Cohen H, Assali A, et al. The effect of cardiac angiography timing, contrast media dose, and preoperative renal function on acute renal failure after coronary artery bypass grafting. *J Thorac Cardiovasc Surg*;139(6):1539–44.
396. Sajja LR, Mannam G, Chakravarthi RM, et al. Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study. *J Thorac Cardiovasc Surg* 2007;133(2):378–88.

397. Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. *Circ Cardiovasc Interv* 2011;4(5):456–62.
398. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med* 2003;348(6):491–9.
399. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. *J Am Coll Cardiol* 2006;48(5):924–30.
400. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. *Circulation* 2007;115(25):3189–96.
401. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. Results from Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome (PRATO-ACS Study). *J Am Coll Cardiol* 2014;63(1):71–9.
402. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. *J Am Coll Cardiol* 2006;48(4):692–9.
403. Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. *Circulation* 2011;124(11):1260–9.
404. Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. *JACC Cardiovasc Interv* 2012;5(1):90–7.
405. ACT-Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). *Circulation* 2011;124(11):1250–9.
406. Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. *Eur Heart J* 2012;33(16):2071–9.
407. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrastagent-induced nephropathy by hemofiltration. *N Engl J Med* 2003;349(14):1333–40.
408. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. *Am J Med* 2006;119(2):155–62.
409. Cruz DN, Goh CY, Marenzi G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. *Am J Med* 2012;125(1):p66–78, e3.
410. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. *Am J Med* 2001;111(9):692–8.
411. Vahanian A, Alferi O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 2012;33(19):2451–96.
412. Czer LS, Gray RJ, Stewart ME, et al. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. *J Thorac Cardiovasc Surg* 1988;95(3):390–401.
413. Iung B, Drissis MF, Michel PL, et al. Prognosis of valve replacement for aortic stenosis with or without coexisting coronary heart disease: a comparative study. *J Heart Valve Dis* 1993;2(4):430–9.
414. Lund O, Nielsen TT, Pilegaard HK, et al. The influence of coronary artery disease and bypass grafting on early and late survival after valve replacement for aortic stenosis. *J Thorac Cardiovasc Surg* 1990;100(3):327–337.
415. Mullany CJ, Elveback LR, Frye RL, et al. Coronary artery disease and its management: influence on survival in patients undergoing aortic valve replacement. *J Am Coll Cardiol* 1987;10(1):66–72.
416. Hannan EL, Wu C, Bennett EV, et al. Risk index for predicting in-hospital mortality for cardiac valve surgery. *Ann Thorac Surg* 2007;83(3):921–29.
417. van Gameren M, Kappetein AP, Steyerberg EW, et al. Do we need separate risk stratification models for hospital mortality after heart valve surgery? *Ann Thorac Surg* 2008;85(3):921–30.
418. Hamm CW, Mollmann H, Holzhey D, et al. The German Aortic Valve Registry (GARY): in-hospital outcome. *Eur Heart J* 2014;35:1588–98.
419. Beach JM, Mihaljevic T, Svensson LG, et al. Coronary artery disease outcomes of aortic valve replacement for severe aortic stenosis. *J Am Coll Cardiol* 2013;61(8):837–48.
420. D'Ascenzo F, Conrotto F, Giordana F, et al. Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A meta-analysis of adjusted observational results. *Int J Cardiol* 2013;168(3):2528–32.
421. Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX-score in patients undergoing transcatheter aortic valve implantation. *Eur Heart J* 2014. Published online 28 March 2014; doi:1093/eurheartj/ehu074.
422. Wenaweser P, Pilgrim T, Guerios E, et al. Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. *EuroIntervention* 2011;7(5):541–8.
423. Abdel-Wahab M, Mostafa AE, Geist V, et al. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation vs. combined with preprocedural percutaneous coronary intervention. *Am J Cardiol* 2012;109(4):581–6.
424. Conradi L, Seiffert M, Franzen O, et al. First experience with transcatheter aortic valve implantation and concomitant percutaneous coronary intervention. *Clin Res Cardiol* 2011;100(4):311–6.
425. Van Mieghem NM, van der Boon RM, Faqiri E, et al. Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. *JACC Cardiovasc Interv* 2013;6(8):867–75.
426. Gautier M, Pepin M, Himbert D, et al. Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. *EuroIntervention* 2011;7(5):549–55.
427. Pasic M, Unbehaun A, Drews T, Hetzer R. Late wound healing problems after use of BioGlue for apical hemostasis during transapical aortic valve implantation. *Interact Cardiovasc Thorac Surg* 2011;13(5):532–34.
428. Pasic M, Dreyse S, Unbehaun A, et al. Combined elective percutaneous coronary intervention and transapical transcatheter aortic valve implantation. *Interact Cardiovasc Thorac Surg* 2012;14(4):463–8.
429. Goel SS, Ige M, Tuzcu EM, et al. Severe aortic stenosis and coronary artery disease: implications for management in the transcatheter aortic valve replacement era: a comprehensive review. *J Am Coll Cardiol* 2013;62(1):1–10.
430. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures. *JACC Cardiovasc Interv* 2008;1(5):459–68.
431. Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. *Circulation* 2012;125(21):2639–48.
432. Chan KM, Punjabi PP, Flather M, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. *Circulation* 2012;126(21):2502–10.
433. Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary artery disease. *Presse Med* 2009;38(6):977–86.
434. Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy: an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2005;65(6):794–801.
435. Li Y, Walicki D, Mathiesen C, et al. Strokes after cardiac surgery and relationship to carotid stenosis. *Arch Neurol* 2009;66(9):1091–6.
436. Tarakji KG, Sabik JF 3rd, Bhudia SK, et al. Temporal onset, risk factors, and outcomes associated with stroke after coronary artery bypass grafting. *JAMA* 2011;305(4):381–90.
437. Ratib K, Mamas MA, Routledge HC, et al. Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention. *Am Heart J* 2013;165(3):317–24.
438. Wardlaw JM, Chappell FM, Stevenson M, et al. Accurate, practical and cost-effective assessment of carotid stenosis in the UK. *Health Technol Assess* 2006;10(30):iii–iv, ix–x, 1–182.
439. Zingone B, Rauber E, Gatti G, et al. The impact of epiaortic ultrasonographic scanning on the risk of perioperative stroke. *Eur J Cardiothorac Surg* 2006;29(5):720–8.
440. Marui A, Okabayashi H, Komiya T, et al. Benefits of off-pump coronary artery bypass grafting in high-risk patients. *Circulation* 2012;126(11 Suppl 1):S151–7.
441. Lamy A, Devereaux PJ, Prabhakaran D, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. *N Engl J Med* 2012;366(16):1489–97.
442. Emmert MY, Seifert B, Wilhelm M, et al. Aortic no-touch technique makes the difference in off-pump coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2011;142(6):1499–1506.
443. Misfeld M, Brereton RJ, Sweetman EA, Doig GS. Neurologic complications after off-pump coronary artery bypass grafting with and without aortic manipulation: meta-analysis of 11,398 cases from 8 studies. *J Thorac Cardiovasc Surg* 2011;142(2):e11–e17.
444. Bouchard D, Carrier M, Demers P, et al. Statin in combination with beta-blocker therapy reduces postoperative stroke after coronary artery bypass graft surgery. *Ann Thorac Surg* 2011;91(3):654–9.
445. Ederle J, Featherstone RL, Brown MM. Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review. *Stroke* 2009;40(4):1373–80.
446. Ederle J, Dobson J, Featherstone RL, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. *Lancet* 2010;375(9719):985–97.
447. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting vs. endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med* 2010;363(1):11–23.
448. Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. *Cochrane Database Syst Rev* 2012;9:CD000515.
449. Shishebor MH, Venkatchalam S, Sun Z, et al. A Direct Comparison of Early and Late Outcomes with Three Approaches to Carotid Revascularization and Open Heart Surgery. *J Am Coll Cardiol* 2013;62(21):1948–56.
450. Nallamothu BK, Gurm HS, Ting HH, et al. Operator experience and carotid stenting outcomes in Medicare beneficiaries. *JAMA* 2011;306(12):1338–43.

451. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32(22):2851–906.
452. Ziada KM, Yadav JS, Mukherjee D, et al. Comparison of results of carotid stenting followed by open heart surgery vs. combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). *Am J Cardiol* 2005;96(4):519–23.
453. Don CW, House J, White C, et al. Carotid revascularization immediately before urgent cardiac surgery practice patterns associated with the choice of carotid artery stenting or endarterectomy: a report from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. *JACC Cardiovasc Interv* 2011;4(11):1200–8.
454. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324(7329):71–86.
455. Dalainas I, Nano G, Bianchi P, et al. Dual antiplatelet regime vs. acetyl-acetic acid for carotid artery stenting. *Cardiovasc Intervent Radiol* 2006;29(4):519–21.
456. McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. *Eur J Vasc Endovasc Surg* 2005;29(5):522–7.
457. Parikh SV, Saya S, Divanji P, et al. Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). *Am J Cardiol* 2011;107(7):959–64.
458. Brilakis ES, Hernandez AF, Dai D, et al. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. *Circulation* 2009;120(7):560–7.
459. Diehm N, Schmidli J, Setacci C, et al. Chapter III: Management of cardiovascular risk factors and medical therapy. *Eur J Vasc Endovasc Surg* 2011;42 Suppl 2:S33–42.
460. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med* 2004;351(27):2795–804.
461. Monaco M, Stassano P, Di Tommaso L, et al. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. *J Am Coll Cardiol* 2009;54(11):989–96.
462. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. *Circulation* 2009;120(21):e169–e276.
463. Zhao DX, Leacche M, Balaguer JM, et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. *J Am Coll Cardiol* 2009;53(3):232–41.
464. Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. *Eur J Cardiothorac Surg* 2006;30(1):117–25.
465. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33(20):2551–67.
466. Davierwala PM, Verevkin A, Leontyev S, et al. Impact of expeditious management of perioperative myocardial ischemia in patients undergoing isolated coronary artery bypass surgery. *Circulation* 2013;128(11 Suppl 1):S226–34.
467. Lafamme M, DeMey N, Bouchard D, et al. Management of early postoperative coronary artery bypass graft failure. *Interact Cardiovasc Thorac Surg* 2012;14(4):452–6.
468. Subramanian S, Sabik JF 3rd, Houghtaling PL, et al. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. *Ann Thorac Surg* 2009;87(5):1392–8; discussion 1400.
469. Desai ND, Cohen EA, Naylor CD, et al. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. *N Engl J Med* 2004;351(22):2302–9.
470. Deb S, Cohen EA, Singh SK, et al. Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). *J Am Coll Cardiol* 2012;60(1):28–35.
471. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. *Ann Thorac Surg* 2004;77(1):93–101.
472. Hattler B, Messenger JC, Shroyer AL, et al. Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. *Circulation* 2012;125(23):2827–35.
473. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. *JAMA* 2005;294(19):2446–54.
474. Tatoulis J, Buxton BF, Fuller JA. The right internal thoracic artery: the forgotten conduit: 5,766 patients and 991 angiograms. *Ann Thorac Surg* 2011;92(1):9–15; discussion 15–17.
475. Barner HB, Bailey M, Guthrie TJ, et al. Radial artery free and T graft patency as coronary artery bypass conduit over a 15-year period. *Circulation* 2012;126(11 Suppl 1):S140–4.
476. Achouh P, Boutekadjirt R, Toledano D, et al. Long-term (5- to 20-year) patency of the radial artery for coronary bypass grafting. *J Thorac Cardiovasc Surg* 2010;140(1):73–79, 79 e1–e2.
477. Sabik JF 3rd, Blackstone EH, Houghtaling PL, et al. Is reoperation still a risk factor in coronary artery bypass surgery? *Ann Thorac Surg* 2005;80(5):1719–27.
478. Yap CH, Sposato L, Akowuah E, et al. Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. *Ann Thorac Surg* 2009;87(5):1386–91.
479. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention vs. repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. *J Am Coll Cardiol* 2002;40(11):1951–4.
480. Harskamp RE, Beijk MA, Damman P, et al. Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. *J Cardiovasc Med (Hagerstown)* 2013;14(6):438–45.
481. Sabik JF 3rd, Raza S, Blackstone EH, et al. Value of internal thoracic artery grafting to the left anterior descending coronary artery at coronary reoperation. *J Am Coll Cardiol* 2013;61(3):302–10.
482. Coolong A, Baim DS, Kuntz RE, et al. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. *Circulation* 2008;117(6):790–7.
483. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. *Circulation* 2002;106(24):3063–7.
484. Baim DS, Wahr D, George B, et al. Saphenous vein graft Angioplasty Free of Emboli Randomized Trial I. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 2002;105(11):1285–190.
485. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. *Circulation* 2003;108(5):548–53.
486. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. *J Am Coll Cardiol* 2007;50(15):1442–9.
487. Naidu SS, Turco MA, Mauri L, et al. Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMETHYST trial substudy). *Am J Cardiol* 2010;105(8):1060–4.
488. Giugliano GR, Falcone MW, Mego D, et al. A prospective multicenter registry of laser therapy for degenerated saphenous vein graft stenosis: the COronary graft Results following Atherectomy with Laser (CORAL) trial. *Cardiovasc Revasc Med* 2012;13(2):84–9.
489. Frobert O, Schersten F, James SK, et al. Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts. *Am Heart J* 2012;164(1):87–93.
490. Wisanan ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents vs. baremetal stents in saphenous vein graft interventions: a systematic review and meta-analysis. *JACC Cardiovasc Interv* 2010;3(12):1262–73.
491. Brilakis ES, Lichtenwalter C, Abdel-karim AR, et al. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. *JACC Cardiovasc Interv* 2011;4(2):176–82.
492. Hakeem A, Helmy T, Munsif S, et al. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. *Catheter Cardiovasc Interv* 2011;77(3):343–55.
493. Mamas MA, Foley J, Nair S, et al. A comparison of drug-eluting stents vs. bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis. *J Interv Cardiol* 2011;24(2):172–80.
494. Ko DT, Guo H, Wijeyesundera HC, et al. Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study. *JACC Cardiovasc Interv* 2011;4(9):965–73.
495. Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting vs. bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet* 2011;378(9796):1071–8.
496. Nauta ST, Van Mieghem NM, Magro M, et al. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts. *Catheter Cardiovasc Interv* 2012;79(6):912–8.
497. Alam M, Bandeali SJ, Virani SS, et al. Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-eluting stents compared to bare-metal stents: a comprehensive meta-analysis of all randomized clinical trials. *Clin Cardiol* 2012;35(5):291–6.
498. Brilakis ES, Lasala JM, Cox DA, et al. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. *JACC Cardiovasc Interv* 2010;3(7):742–50.
499. Seshadri N, Whitlow PL, Acharya N, et al. Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. *Circulation* 2002;106(18):2346–50.

500. Richardson SG, Morton P, Murtagh JG, et al. Management of acute coronary occlusion during percutaneous transluminal coronary angioplasty: experience of complications in a hospital without on site facilities for cardiac surgery. *BMJ* 1990;300(6721):355–8.
501. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;293(2):165–71.
502. Mehilli J, Byrne RA, Tiroch K, et al. A randomized trial of paclitaxel- vs. sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 2010;55(24):2710–6.
503. Alfonso F, Perez-Vizcaino MJ, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Vs. Elective Sirolimus-Eluting Stenting (RIBS-II) trial. *J Am Coll Cardiol* 2006;47(11):2152–60.
504. Alfonso F, Zueco J, Cequier A, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol* 2003;42(5):796–805.
505. Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. *J Am Coll Cardiol* 2007;49(5):616–23.
506. Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *JACC Cardiovasc Interv* 2012;5(3):323–30.
507. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med* 2006;355(20):2113–24.
508. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter vs. paclitaxel-coated stent for the treatment of coronary in-stent restenosis. *Circulation* 2009;119(23):2986–94.
509. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol* 2012;59(15):1377–82.
510. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. *JACC Cardiovasc Interv* 2011;4(2):149–54.
511. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISARDESIRE 3): a randomised, open-label trial. *Lancet* 2013;381(9865):461–7.
512. Indermuehle A, Bahl R, Lansky AJ, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. *Heart* 2013;99(5):327–33.
513. Tousek P, Pavei A, Oreglia J, et al. Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era. *EuroIntervention* 2009;4(5):588–92.
514. Zellweger MJ, Kaiser C, Jeger R, et al. Coronary artery disease progression late after successful stent implantation. *J Am Coll Cardiol* 2012;59(9):793–9.
515. Chechi T, Vecchio S, Vittori G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. *J Am Coll Cardiol* 2008;51(25):2396–402.
516. Alfonso F, Dutary J, Paulo M, Gonzalo N, et al. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. *Heart* 2012;98(16):1213–20.
517. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. *JACC Cardiovasc Interv* 2012;5(2):131–40.
518. Nwiott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357(20):2001–15.
519. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*. 2010;363(10):930–42.
520. Bonatti JO, Zimir D, Lehr EJ, et al. Hybrid coronary revascularization using robotic totally endoscopic surgery: perioperative outcomes and 5-year results. *Ann Thorac Surg* 2012;94(6):1920–6; discussion 1926.
521. Shen L, Hu S, Wang H, Xiong H, et al. One-stop hybrid coronary revascularization vs. coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution. *J Am Coll Cardiol* 2013;61(25):2525–33.
522. Harskamp RE, Bonatti JO, Zhao DX, et al. Standardizing definitions for hybrid coronary revascularization. *J Thorac Cardiovasc Surg* 2014;147(2):556–60.
523. Zembala M, Tajstra M, Filipiak K, et al. Prospective randomised pIIot study evaluating the safety and efficacy of hybrid revascularisation in Multi-vessel coronary artery Disease (POLMIDES) - study design. *Kardiol Pol* 2011;69(5):460–6.
524. Alfonso F, Perez-Vizcaino MJ, Cardenas A, et al. Randomized Comparison of Drug-Eluting Balloon Vs. Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial. *J Am Coll Cardiol* 2014;63(14):1378–86.
525. Holmes DR Jr., Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. *Circulation* 1986;73(6):1254–63.
526. Veenhuizen GD, Singh SN, McAreavey D, et al. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. *Circulation* 2001;104(13):1489–93.
527. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. *Coronary Artery Bypass Graft (CABG) Patch Trial Investigators*. *N Engl J Med* 1997;337(22):1569–75.
528. Barsheshet A, Goldenberg I, Moss AJ, et al. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial. *J Cardiovasc Electrophysiol* 2011;22(11):1237–42.
529. Al-Khatib SM, Hellkamp AS, Lee KL, et al. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *J Cardiovasc Electrophysiol* 2008;19(10):1059–65.
530. Funaro S, La Torre G, Madonna M, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. *Eur Heart J* 2009;30(5):566–75.
531. Antoni ML, Mollema SA, Delgado V, et al. Prognostic importance of strain and strain rate after acute myocardial infarction. *Eur Heart J* 2010;31(13):1640–7.
532. Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. *Heart Rhythm* 2007;4(11):1395–102.
533. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. *N Engl J Med* 1997;336(23):1629–33.
534. Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest. *JACC Cardiovasc Interv* 2012;5(6):597–605.
535. Garot P, Lefevre T, Eltchaninoff H, et al. Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. *Circulation* 2007;115(11):1354–62.
536. Radsel P, Knafelj R, Kocjancic S, Noc M. Angiographic characteristics of coronary disease and postresuscitation electrocardiograms in patients with aborted cardiac arrest outside a hospital. *Am J Cardiol* 2011;108(5):634–8.
537. Anyfantakis ZA, Baron G, Aubry P, et al. Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest. *Am Heart J* 2009;157(2):312–8.
538. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac Arrest) registry. *Circ Cardiovasc Interv* 2010;3(3):200–7.
539. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. *Crit Care* 2011;15(3):R122.
540. Noc M, Fajadet J, Lassen JF, et al. Invasive Coronary Treatment Strategies for Out-Of-Hospital Cardiac Arrest: A Consensus Statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. *EuroIntervention* 2014;10:31–7.
541. Mrdovic I, Savic L, Krljanac G, et al. Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial. *Coron Artery Dis* 2012;23(1):1–8.
542. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. *Eur Heart J* 2009;30(16):2019–28.
543. Chan W, Ajani AE, Clark DJ, et al. Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention. *Am J Cardiol* 2012;109(4):471–7.
544. Pilgrim T, Kalessan B, Zanchin T, et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. *EuroIntervention* 2013;8(9):1061–71.
545. Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. *Thromb Haemost* 2013;110(3):560–8.
546. Ruiz-Nodar JM, Marin F, Roldan V, et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? *Circ Cardiovasc Interv* 2012;5(4):459–66.
547. Camm AJ, Lip GY, De Caterina R, et al. Guidelines ESC/EF 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33(21):2719–47.
548. Shen J, Lall S, Zheng V, et al. The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. *J Thorac Cardiovasc Surg* 2011;141(2):559–70.
549. Maesen B, Nijs J, Maessen J, et al. Postoperative atrial fibrillation: a maze of mechanisms. *Europace* 2012;14(2):159–74.
550. Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. *Circulation* 2008;118(16):1612–8.
551. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of postoperative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. *Eur Heart J* 2006;27(23):2846–57.

552. Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. *Circulation* 2002;106(1):75–80.
553. Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. *Am Heart J* 2003;145(2):226–32.
554. Lucio EA, Flores A, Blacher C, et al. Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery. *Arq Bras Cardiol* 2003;82:42–6.
555. Tsuboi J, Kawazoe K, Izumoto H, Okabayashi H. Postoperative treatment with carvedilol, a-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. *Circ J* 2008;72:588–91.
556. Konjari I, Apostolakis E, Rogkakou C, et al. Pharmacologic prophylaxis for atrial fibrillation following cardiac surgery: a systematic review. *J Cardiothorac Surg* 2010;5:121.
557. Dunning J, Treasure T, Versteegh M, Nashed SA. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. *Eur J Cardiothorac Surg* 2006;30:852–72.
558. Wurdeman RL, Mooss AN, Mohiuddin SM, Lenz TL. Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. *Chest* 2002;121(4):1203–10.
559. Zhu J, Wang C, Gao D, et al. Meta-analysis of amiodarone vs. beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. *Intern Med J* 2012;42(10):1078–87.
560. El-Chami MF, Kilgo P, Thourani V, et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. *J Am Coll Cardiol* 2010;55(13):1370–6.
561. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. *Eur Heart J* 2009;30(24):2969–77c.
562. Cox JL, AdN, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. *J Thorac Cardiovasc Surg* 1999;118(5):833–40.
563. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. *J Am Coll Cardiol* 2003;42(7):1253–8.
564. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. *Lancet* 2009;374(9689):534–42.
565. Bagshaw SM, Galbraith PD, Mitchell LB, et al. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. *Ann Thorac Surg* 2006;82:1927–37.
566. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation* 2011;123:417–24.
567. Otterstad JE, Kirwan BA, Lubsen J, et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. *Scand Cardiovasc J* 2006;40(3):152–9.
568. Goldenberg I, Moss AJ, McNitt S, et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. *J Am Coll Cardiol* 2006;47(9):1811–7.
569. Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. *Anesth Analg* 2009;109(2):320–30.
570. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. *Br J Anaesth* 2009;102(2):168–178.
571. Bhaskar B, Bulhunty J, Mullany DV, Fraser JF. Impact of blood product transfusion on short and long-term survival after cardiac surgery: more evidence. *Ann Thorac Surg* 2012;94(2):460–7.
572. Jakobsen CJ, Ryhammer PK, Tang M, et al. Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients. *Eur J Cardiothorac Surg* 2012;42(1):114–20.
573. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. *JAMA* 2010;304(14):1559–67.
574. Zenati MA, Shroyer AL, Collins JF, et al. Impact of endoscopic vs. open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. *J Thorac Cardiovasc Surg* 2011;141(2):338–44.
575. Lopes RD, Hafley GE, Allen KB, et al. Endoscopic vs. Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery. *NEng J Med* 2009;361(3):235–44.
576. Deppe AC, Liakopoulos OJ, Choi YH, et al. Endoscopic vein harvesting for coronary artery bypass grafting: a systematic review with meta-analysis of 27,789 patients. *J Surg Res* 2012;180(1):114–24.
577. Yun KL, Wu Y, Aharonian V, et al. Randomized trial of endoscopic vs. open vein harvest for coronary artery bypass grafting: six-month patency rates. *J Thorac Cardiovasc Surg* 2005;129(3):496–503.
578. Ouzounian M, Hassan A, Buth KJ, et al. Impact of endoscopic vs. open saphenous vein harvest techniques on outcomes after coronary artery bypass grafting. *Ann Thorac Surg* 2010;89(2):403–8.
579. Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs. open vein-graft harvesting and mortality, wound complications and cardiovascular events in patients undergoing CABG surgery. *JAMA* 2012;308(5):475–84.
580. Brown EN, Kon ZN, Tran R, et al. Strategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins. *J Thorac Cardiovasc Surg* 2007;134(5):1259–65.
581. Khaleel MS, Dorheim TA, Duryee MJ, et al. High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure. *Ann Thorac Surg* 2012;93(2):552–8.
582. Rousou LJ, Taylor KB, Lu XG, et al. Saphenous vein conduits harvested by endoscopic technique exhibit structural and functional damage. *Ann Thorac Surg* 2009;87(1):62–70.
583. Navia JL, Olivares G, Ehasz P, et al. Endoscopic radial artery harvesting procedure for coronary artery bypass grafting. *Ann Cardiothorac Surg* 2013;2(4):557–64.
584. Souza DS, Dashwood MR, Tsui JC, et al. Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. *Ann Thorac Surg* 2002;73(4):1189–95.
585. Johansson BL, Souza DS, Bodin L, et al. Slower progression of atherosclerosis in vein grafts harvested with 'no touch' technique compared with conventional harvesting technique in coronary artery bypass grafting: an angiographic and intravascular ultrasound study. *Eur J Cardiothorac Surg* 2010;38(4):414–9.
586. Deo SV, Shah IK, Dunlay SM, et al. Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. *Ann Thorac Surg* 2013;95(3):862–9.
587. SaMP, Ferraz PE, Escobar RR, et al. Skeletonized vs. pedicled internal thoracic artery and risk of sternal wound infection after coronary bypass surgery: meta-analysis and meta-regression of 4817 patients. *Interact Cardiovasc Thorac Surg* 2013;16(6):849–57.
588. Sakic A, Chevtchik O, Kilo J, et al. Simple adaptations of surgical technique to critically reduce the risk of postoperative sternal complications in patients receiving bilateral internal thoracic arteries. *Interact Cardiovasc Thorac Surg* 2013;17(2):378–82.
589. Lytle BW. Skeletonized internal thoracic artery grafts and wound complications. *J Thorac Cardiovasc Surg* 2001;121(4):625–27.
590. Wendler O, Hennen B, Markwirth T, et al. T grafts with the right internal thoracic artery to left internal thoracic artery vs. the left internal thoracic artery and radial artery: flow dynamics in the internal thoracic artery main stem. *J Thorac Cardiovasc Surg* 1999;118(5):841–8.
591. Taggart DP. Incomplete revascularization: appropriate and inappropriate. *Eur J Cardiothorac Surg* 2012;41(3):542–3.
592. Zimarino M, Curzen N, Cicchitti V, De Caterina R. The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. *Int J Cardiol* 2013;168(3):1748–57.
593. Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery vs. percutaneous coronary intervention. *Circulation* 2006;114(3):249–55.
594. Farooq V, Serruys PW, Garcia-Garcia HM, et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. *J Am Coll Cardiol* 2013;61(3):282–94.
595. Head SJ, Mack MJ, Holmes DR Jr, et al. Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. *Eur J Cardiothorac Surg* 2012;41(3):535–41.
596. Kim YH, Park DW, Lee JY, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. *Circulation* 2011;123(21):2373–81.
597. Mohammadi S, Kalavrouziotis D, Dagenais F, et al. Completeness of revascularization and survival among octogenarians with triple-vessel disease. *Ann Thorac Surg* 2012;93(5):1432–7.
598. Yi G, Youn YN, Joo HC, et al. Association of incomplete revascularization with long-term survival after off-pump coronary artery bypass grafting. *J Surg Res* 2013;185(1):166–73.
599. Rastan AJ, Walther T, Falk V, et al. Does reasonable incomplete surgical revascularization affect early or long-term survival in patients with multivessel coronary artery disease receiving left internal mammary artery bypass to left anterior descending artery? *Circulation* 2009;120(11 Suppl):S70–77.
600. Garcia S, Sandoval Y, Roukoz H, et al. Outcomes after complete vs. incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. *J Am Coll Cardiol* 2013;62(16):1421–31.
601. Scott R, Blackstone EH, McCarthy PM, et al. Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery. *J Thorac Cardiovasc Surg* 2000;120(1):173–84.
602. Boylan MJ, Lytle BW, Loop FD, et al. Surgical treatment of isolated left anterior descending coronary stenosis. Comparison of left internal mammary artery and venous autograft at 18 to 20 years of follow-up. *J Thorac Cardiovasc Surg*. 1994;107:657–62.
603. Sabik JF 3rd, Blackstone EH, Gillinov AM, et al. Influence of patient characteristics and arterial grafts on freedom from coronary reoperation. *J Thorac Cardiovasc Surg* 2006;131(1):90–8.
604. Schmitto JD, Rajab TK, Cohn LH. Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft. *Curr Opin Cardiol* 2010;25(6):609–12.

605. Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. *Lancet* 2001;358(9285):870–5.
606. Ruttman E, Fischler N, Sakic A, et al. Second internal thoracic artery vs. radial artery in coronary artery bypass grafting: a long-term, propensity score-matched follow-up study. *Circulation* 2011;124(12):1321–9.
607. Galbut DL, Kurlansky PA, Traad EA, et al. Bilateral internal thoracic artery grafting improves long-term survival in patients with reduced ejection fraction: a propensity-matched study with 30-year follow-up. *J Thorac Cardiovasc Surg* 2012;143(4):844–53 e4.
608. Grau JB, Ferrari G, Mak AW, et al. Propensity matched analysis of bilateral internal mammary artery vs. single left internal mammary artery grafting at 17-year follow-up: validation of a contemporary surgical experience. *Eur J Cardiothorac Surg* 2012;41(4):770–5, discussion 776.
609. Lytle BW. Bilateral internal thoracic artery grafting. *Ann Cardiothorac Surg* 2013;2(4):485–92.
610. Weiss AJ, Zhao S, Tian DH, et al. A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting. *Ann Cardiothorac Surg* 2013;2(4):390–400.
611. Hemo E, Mohr R, Uretzky G, et al. Long-term outcomes of patients with diabetes receiving bilateral internal thoracic artery grafts. *J Thorac Cardiovasc Surg* 2013;146(3):586–92.
612. Taggart DP, Lees B, Gray A, et al. Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral vs. single internal mammary grafting in coronary revascularisation [ISRCTN46552265]. *Trials* 2006;7:7.
613. Elmistekawy EM, Gawad N, Bourke M, et al. Is bilateral internal thoracic artery use safe in the elderly? *J Card Surg* 2012;27(1):1–5.
614. Toumpoulis IK, Theakos N, Dunning J. Does bilateral internal thoracic artery harvest increase the risk of mediastinitis? *Interact Cardiovasc Thorac Surg* 2007;6(6):787–91.
615. Tranbaugh RF, Dimitrova KR, Friedmann P, et al. Radial artery conduits improve long-term survival after coronary artery bypass grafting. *Ann Thorac Surg* 2010;90(4):1165–72.
616. Tranbaugh RF, Dimitrova KR, Friedmann P, et al. Coronary artery bypass grafting using the radial artery: clinical outcomes, patency, and need for reintervention. *Circulation* 2012;126(11 Suppl 1):S170–5.
617. Schwann TA, Engoren M, Bonnell M, et al. Comparison of late coronary artery bypass graft survival effects of radial artery vs. saphenous vein grafting in male and female patients. *Ann Thorac Surg* 2012;94(5):1485–91.
618. Hayward PA, Gordon IR, Hare DL, et al. Comparable patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 years: results from the Radial Artery Patency and Clinical Outcomes trial. *J Thorac Cardiovasc Surg* 2010;139(1):60–5; discussion 65–7.
619. Kieser TM, Rose S, Kowalewski R, Belenkie I. Transit-time flow predicts outcomes in coronary artery bypass graft patients: a series of 1000 consecutive arterial grafts. *Eur J Cardiothorac Surg* 2010;38(2):155–62.
620. Jokinen JJ, Werkkala K, Vainikka T, et al. Clinical value of intra-operative transit-time flow measurement for coronary artery bypass grafting: a prospective angiography-controlled study. *Eur J Cardiothorac Surg* 2011;39(6):918–23.
621. Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. *N Engl J Med* 2013;368(13):1179–88.
622. Diegeler A, Borgermann J, Kappert U, et al. Off-pump vs. on-pump coronary-artery bypass grafting in elderly patients. *N Engl J Med* 2013;368(13):1189–98.
623. Shroyer AL, Grover FL, Hattler B, et al. On-pump vs. off-pump coronary-artery bypass surgery. *N Engl J Med* 2009;361(19):1827–37.
624. Houliand K, Kjeldsen BJ, Madsen SN, et al. On-pump vs. off-pump coronary artery bypass surgery in elderly patients: results from the Danish on-pump vs. off-pump randomization study. *Circulation* 2012;125(20):2431–9.
625. Hattler B, Messenger JC, Shroyer AL, et al. Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. *Circulation* 2012;125(23):2827–35.
626. Sedrakyan A, Wu AW, Parashar A, et al. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials. *Stroke* 2006;37(11):2759–69.
627. Keeling WB, Kilgo PD, Puskas JD, et al. Off-pump coronary artery bypass grafting attenuates morbidity and mortality for patients with low and high body mass index. *J Thorac Cardiovasc Surg* 2012;146(6):1142–8.
628. Puskas JD, Williams WH, O'Donnell R, et al. Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: long-term follow-up of a randomized trial. *Ann Thorac Surg* 2011;91(6):1836–1842; discussion 1842–3.
629. Puskas JD, Thourani VH, Kilgo P, et al. Off-pump coronary artery bypass disproportionately benefits high-risk patients. *Ann Thorac Surg* 2009;88(4):1142–7.
630. Head SJ, Borgermann J, Osnabrugge RL, et al. Coronary artery bypass grafting: Part 2: optimizing outcomes and future prospects. *Eur Heart J* 2013;34(37):2873–86.
631. Diegeler A, Walther T, Metz S, et al. Comparison of MIDCAP vs. conventional CABG surgery regarding pain and quality of life. *Heart Surg Forum* 1999;2(4):290–295; discussion 295–6.
632. Groh MA, Sutherland SE, Burton HG 3rd, et al. Port-access coronary artery bypass grafting: technique and comparative results. *Ann Thorac Surg* 1999;68(4):1506–8.
633. Lapiere H, Chan V, Sohmer B, et al. Minimally invasive coronary artery bypass grafting via a small thoracotomy vs. off-pump: a case-matched study. *Eur J Cardiothorac Surg* 2011;40(4):804–10.
634. Siregar S, Groenwold RH, de Mol BA, et al. Evaluation of cardiac surgery mortality rates: 30-day mortality or longer follow-up? *Eur J Cardiothorac Surg* 2013;44(5):875–83.
635. Peterson ED, Coombs LP, DeLong ER, et al. Procedural volume as a marker of quality for CABG surgery. *JAMA* 2004;291(2):195–201.
636. Sergeant P, Blackstone E, Meyns B. Validation and interdependence with patient variables of the influence of procedural variables on early and late survival after CABG. *K. U. Leuven Coronary Surgery Program. Eur J Cardiothorac Surg* 1997;12(1):1–19.
637. Williams JB, Peterson ED, Brennan JM, et al. Association Between Endoscopic vs. Open Vein-Graft Harvesting and Mortality, Wound Complications, and Cardiovascular Events in Patients Undergoing CABG Surgery. *JAMA* 2012;308(5):475–84.
638. Bakaeen FG. Endoscopic vein harvest for coronary artery bypass grafting is safe. *J Surg Res* 2013;185(2):522–523.
639. Schmitto JD, Rajab TK, Cohn LH. Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft. *Curr Opin Cardiol* 2010;25:609–12.
640. Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral Internal Mammary Artery Grafting Enhances Survival in Diabetic Patients: A 30-Year Follow-Up of Propensity Score 2-Matched Cohorts. *Circulation* 2012;126:2935–42.
641. Kieser TM, Lewin AM, Graham MM, et al. Outcomes associated with bilateral internal thoracic artery grafting: the importance of age. *Ann Thorac Surg* 2011;92(4):1269–1275; discussion 1275–6.
642. Desai ND, Cohen EA, Naylor CD, Fremes SE. A Randomized Comparison of Radial-Artery and Saphenous-Vein Coronary Bypass Grafts. *N Engl J Med* 2004;351:2302–9.
643. Tatoulis J. Total arterial coronary revascularization-patient selection, stenoses, conduits, targets. *Ann Cardiothorac Surg* 2013;2(4):499–506.
644. Borgermann J, Hakim K, Renner A, et al. Clamless off-pump vs. conventional coronary artery revascularization: a propensity score analysis of 788 patients. *Circulation* 2012;126(11 Suppl 1):S176–82.
645. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. *Ann Intern Med* 2003;138(10):777–86.
646. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. *Circulation* 2001;103(23):2816–21.
647. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J Am Coll Cardiol* 2003;41(8):1283–8.
648. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 2013;382(9906):1714–22.
649. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med* 2007;356(10):1030–9.
650. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 2007;356(10):998–1008.
651. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institution cohort study. *Lancet* 2007;369(9562):667–78.
652. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs. bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. *Arch Intern Med* 2012;172(8):611–621, discussion 621–2.
653. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. *N Engl J Med* 2012;366(1):54–63.
654. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010;362(18):1663–74.
655. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010; 363(2):136–46.
656. Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent vs. durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. *Lancet* 2013;381(9867):661–9.
657. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 2009;30(20):2441–9.
658. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. *Lancet* 2013;381(9867):651–60.
659. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting vs. new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting vs. Zotarolimus-eluting Stents (ISAR-TEST 5) trial. *Circulation* 2011;124(5):624–32.

660. Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. *Circ Cardiovasc Interv* 2010;3(2):174–83.
661. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. *JACC Cardiovasc Interv* 2011;4(10):1104–15.
662. ParkKW, Kang SH, Velders MA, et al. Safety and efficacy of everolimus- vs. sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. *Am Heart J* 2013;165(2):241–50 e4.
663. HawnMT, Graham LA, Richman JS, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. *JAMA* 2013;310(14):1462–72.
664. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. *J Am Coll Cardiol* 2011;57(16):1700–8.
665. von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, noninferiority trial. *Lancet* 2013;383(9915):413–23.
666. von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents vs. everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. *J Am Coll Cardiol* 2012;59(15):1350–61.
667. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* 2010;375(9710):201–9.
668. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer vs. sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. *Lancet* 2008;372(9644):1163–73.
669. Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. *J Am Coll Cardiol* 2013;62(3):181–90.
670. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of novolimus-eluting and zotarolimuseluting coronary stents: 9-month follow-up results of the EXCELLA II study. *Euro-Intervention* 2010;6(2):195–205.
671. Verheye S, Ramcharitar S, Grube E, et al. Six-month clinical and angiographic results of the STENTYS(R) self-apposing stent in bifurcation lesions. *EuroIntervention* 2011;7(5):580–7.
672. Verheye S, Agostoni P, Dubois CL, et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. *J Am Coll Cardiol* 2009;53(12):1031–9.
673. Buyschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. *EuroIntervention* 2013;9(5):573–81.
674. Dani S, Costa RA, Joshi H, et al. First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the merIT-1 trial. *EuroIntervention* 2013;9(4):493–500.
675. Haude M, Lee SW,Worthley SG, et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. *JACC Cardiovasc Interv* 2013; 6(4):334–43.
676. Vranckx P, SerruysPW, Gambhir S, et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. *EuroIntervention* 2006;2(3):310–7.
677. Ormiston J,Webster M, Stewart J, et al. First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries). *JACC Cardiovasc Interv* 2013;6(10):1026–34.
678. Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic, 30-month clinical follow-up results from the series I prospective study. *EuroIntervention* 2008;4(1):59–63.
679. Seth A, Chandra P, Chouhan NS, Thakkar AS. A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. *Indian Heart J* 2012;64(6):547–52.
680. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. *J Am Coll Cardiol* 2012;59(15):1362–70.
681. Carrie D, Berland J, Verheye S, et al. A multicenter randomized trial comparing amphillimus-with paclitaxel-eluting stents in de novo native coronary artery lesions. *J Am Coll Cardiol* 2012;59(15):1371–6.
682. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent vs. a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;113(2):273–9.
683. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. *JACC Cardiovasc Interv* 2009;2(4):291–9.
684. Garg S, Bourantas C, SerruysPW. New concepts in the design of drug-eluting coronary stents. *Nat Rev Cardiol* 2013;10(5):248–60.
685. Ormiston JA, SerruysPW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. *Lancet* 2008;371(9616):899–907.
686. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. *Lancet* 2009;373(9667):897–910.
687. Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *Lancet* 2013;381(9869):836–44.
688. Verheye S, Ormiston JA, Stewart J, et al. A Next-Generation Bioresorbable Coronary Scaffold System-From Bench to First Clinical Evaluation: Six- and 12-Month Clinical and Multimodality Imaging Results. *JACC Cardiovasc Interv* 2013;7(1):89–99.
689. Maier LS, Maack C, Ritter O, Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008. (PEPCAD,LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN). *Clin Res Cardiol* 2008;97(6):356–63.
690. Fischer D, Scheller B, Schafer A, et al. Paclitaxelcoated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. *EuroIntervention* 2012;8(4):450–55.
691. Belkacemi A, Agostoni P, Nathoe HM, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent vs. bare-metal stent vs. drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. *J Am Coll Cardiol* 2012;59(25):2327–37.
692. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. *J Am Coll Cardiol* 2012;60(24):2473–80.
693. Bondesson P, Lagerqvist B, James SK, et al. Comparison of two drug-eluting balloons: a report from the SCAAR registry. *Euro-Intervention* 2012;8(4):444–9.
694. Stella PR, Belkacemi A,Waksman R, et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIORpaclitaxel drug-eluting balloon for in-stent restenosis treatment. *EuroIntervention* 2011;7(6):705–10.
695. Waksman R, Serra A, Loh JP, et al. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. *EuroIntervention* 2013;9(5):613–9.
696. Gutierrez-Chico JL, van Geuns RJ, Koch KT, et al. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. *EuroIntervention* 2011;7(6):711–22.
697. Hrehlein C, Dietz U, Kubica J, et al. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. *Cardiovasc Revasc Med* 2012;13(5):260–4.
698. Abdel-Wahab M, Richardt G, Joachim Buttner H, et al. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial. *JACC Cardiovasc Interv* 2013;6(1):10–9.
699. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement, Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 2001;37(5):1478–92.
700. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering I. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med* 2005;352(1):29–38.
701. Mintz GS, Garcia-Garcia HM, Nicholls SJ, et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. *EuroIntervention* 2011;6(9):1123–30. 9.
702. Casella G, Klauss V, Ottani F, et al. Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. *Catheter Cardiovasc Interv* 2003;59(3):314–21.
703. Parise H, Maehara A, StoneGW, et al. Meta-analysis of randomized studies comparing intravascular ultrasound vs. angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. *Am J Cardiol* 2011;107(3):374–82.
704. Zhang Y, Farooq V, Garcia-Garcia HM, et al. Comparison of intravascular ultrasound vs. angiographyguided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. *EuroIntervention* 2012;8(7):855–65.

705. Park SJ, Kim YH, Park DW, et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. *Circ Cardiovasc Interv* 2009;2(3):167–77.
706. Witzentrichler B, Maehara A, Weisz G, et al. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Study. *Circulation* 2014;129(4):463–70.
707. Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. *J Am Coll Cardiol* 2012;59(12):1058–72.
708. Cassar A, Matsuo Y, Herrmann J, et al. Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. *Eur Heart J* 2013;34(33):2610–17.
709. Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. *Eur Heart J* 2012;33(20):2513–20.
710. Radu MD, Raber L, Heo J, et al. Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation. *EuroIntervention* 2014;9(9):1085–94.
711. Prati F, Di Vito L, Biondi-Zoccai G, et al. Angiography alone vs. angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. *EuroIntervention* 2012;8(7):823–9.
712. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neointimal hyperplasia after drug-eluting stent implantation. *Circulation* 2011;123(25):2954–63.
713. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med* 1996;334(26):1703–8.
714. Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) study. *J Am Coll Cardiol* 2012;59(15):1392–402.
715. Nakazato R, Park HB, Berman DS, et al. Non-invasive Fractional Flow Reserve Derived from CT Angiography (FFRCT) for Coronary Lesions of Intermediate Stenosis Severity: Results from the DeFACTO study. *Circ Cardiovasc Imaging* 2013;6(6):881–9.
716. Koo BK, Erglis A, Doh JH, et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. *J Am Coll Cardiol* 2011;58(19):1989–97.
717. Patel Y, Depta JP, Novak E, et al. Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions. *Am J Cardiol* 2012;109(7):960–5.
718. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. *J Am Coll Cardiol* 1992;19(7):1641–52.
719. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple vs. complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. *Circulation* 2006;114(18):1955–61.
720. Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? *JACC Cardiovasc Interv* 2008;1(3):218–26.
721. Al Suwaidi J, Yeh W, Cohen HA, et al. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). *Am J Cardiol* 2001;87(10):1139–44.
722. Stinis CT, Hu SP, Price MJ, Teirstein PS. Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions. *Catheter Cardiovasc Interv* 2010;75(3):309–14.
723. Iakovou I, Schmidt T, Bonizzi E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;293(17):2126–30.
724. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation* 2004;109(10):1244–9.
725. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. *J Am Coll Cardiol* 2005;46(8):1446–55.
726. Maeng M, Holm NR, Erglis A, et al. Long-term results after simple vs. complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. *J Am Coll Cardiol* 2013;62(1):30–4.
727. Ferenc M, Gick M, Kienle RP, et al. Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. *Am Heart J* 2010;159(3):454–61.
728. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple vs. complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. *Circulation* 2010;121(10):1235–43.
729. Behan MW, Holm NR, Curzen NP, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. *Circ Cardiovasc Interv* 2011;4(1):57–64.
730. Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush vs. Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. *J Am Coll Cardiol* 2011;57(8):914–20.
731. Assali AR, Vaknin-Assa H, Lev E, et al. Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy. *Catheter Cardiovasc Interv* 2012;79(4):615–22.
732. Song YB, Hahn JY, Song PS, et al. Randomized comparison of conservative vs. aggressive strategy for provisional side branch intervention in coronary bifurcation lesions: results from the SMARTSTRATEGY (Smart Angioplasty Research Team-Optimal Strategy for Side Branch Intervention in Coronary Bifurcation Lesions) randomized trial. *JACC Cardiovasc Interv* 2012;5(11):1133–40.
733. Niemela M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation vs. no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. *Circulation* 2011;123(1):79–86.
734. Gwon HC, Hahn JY, Koo BK, et al. Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. *Heart* 2012;98(3):225–31.
735. Mylotte D, Mefout B, Moynagh A, et al. Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry. *EuroIntervention* 2012;8(8):970–81.
736. Teirstein PS, Price MJ. Left main percutaneous coronary intervention. *J Am Coll Cardiol* 2012;60(17):1605–1613.
737. Chen SL, Zhang Y, Xu B, et al. Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent vs. two-stent techniques vs. double-kissing crush technique. *EuroIntervention* 2012;8(7):803–14.
738. Di Mario C, Werner GS, Sianos G, et al. European perspective in the recanalization of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. *EuroIntervention* 2007;3(1):30–43.
739. Christofferson RD, Lehmann KG, Martin GV, et al. Effect of chronic total coronary occlusion on treatment strategy. *Am J Cardiol* 2005;95(9):1088–91.
740. Claessen BE, Dangas GD, Godino C, et al. Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with vs. without diabetes mellitus. *Am J Cardiol* 2011;108(7):924–31.
741. Mehran R, Claessen BE, Godino C, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. *JACC Cardiovasc Interv* 2011;4(9):952–61.
742. Jones DA, Weerackody R, Rathod K, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. *JACC Cardiovasc Interv* 2012;5(4):380–8.
743. Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. *Am Heart J* 2010;160(1):179–87.
744. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. *Circulation* 2006;113(20):2406–12.
745. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the Flow-Cardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. *Circ Cardiovasc Qual Outcomes* 2010;3(3):284–90.
746. Werner GS, Hochadel M, Zeymer U, et al. Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006. *EuroIntervention* 2010;6(3):361–6.
747. Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. *J Am Coll Cardiol* 2012;59(11):991–7.
748. Morino Y, Kimura T, Hayashi Y, et al. In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). *JACC Cardiovasc Interv* 2010;3(2):143–51.
749. Surmely JF, Tsuchikane E, Katoh O, et al. New concept for CTO recanalization using controlled antegrade and retrograde subintimal tracking: the CART technique. *J Invasive Cardiol* 2006;18(7):334–8.
750. Sianos G, Barlis P, Di Mario C, et al. European experience with the retrograde approach for the recanalisation of coronary artery chronic total occlusions. A report on behalf of the euroCTO club. *EuroIntervention* 2008;4(1):84–92.
751. Colmenarez HJ, Escaned J, Fernandez C, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. *J Am Coll Cardiol* 2010;55(17):1854–66.
752. Saeed B, Kandzari DE, Agostoni P, et al. Use of drug-eluting stents for chronic total occlusions: a systematic review and meta-analysis. *Catheter Cardiovasc Interv* 2011;77(3):315–32.
753. Van den Branden BJ, Rahel BM, Laarman GJ, et al. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). *EuroIntervention* 2012;7(10):1189–96.
754. Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drug-eluting vs. bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005–2008. *JACC Cardiovasc Interv* 2012;5(10):1054–61.

755. Jokhi P, Curzen N. Percutaneous coronary intervention of ostial lesions. *EuroIntervention* 2009;5(4):511-4.

756. Pritchard CL, Mudd JG, Barner HB. Coronary ostial stenosis. *Circulation* 1975;52(1):46-48.

757. Thompson R. Isolated coronary ostial stenosis in women. *J Am Coll Cardiol* 1986;7(5):997-1003.

758. Miller GA, Honey M, el-Sayed H. Isolated coronary ostial stenosis. *Cathet Cardiovasc Diagn* 1986;12(1):30-4.

759. Rissanen V. Occurrence of coronary ostial stenosis in a necropsy series of myocardial infarction, sudden death, and violent death. *Br Heart J* 1975;37(2):182-91.

760. Popma JJ, Dick RJ, Haudenschild CC, et al. Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings. *Am J Cardiol* 1991;67(5):431-3.

761. Koh JS, Koo BK, Kim JH, et al. Relationship between fractional flow reserve and angiographic and intravascular ultrasound parameters in ostial lesions: major epicardial vessel vs. side branch ostial lesions. *JACC Cardiovasc Interv* 2012;5(4):409-15.

762. Muramatsu T, Tsukahara R, Ho M, et al. Efficacy of cutting balloon angioplasty for lesions at the ostium of the coronary arteries. *J Invasive Cardiol* 1999;11(4):201-6.

763. Kurbaan AS, Kelly PA, Sigwart U. Cutting balloon angioplasty and stenting for aorto-ostial lesions. *Heart* 1997;77(4):350-2.

764. Chung CM, Nakamura S, Tanaka K, et al. Comparison of cutting balloon vs. stenting alone in small branch ostial lesions of native coronary arteries. *Circ J* 2003;67(1):21-5.

765. Popma JJ, BroganWC3rd, Pichard AD, et al. Rotational coronary atherectomy of ostial stenoses. *Am J Cardiol* 1993;71(5):436-8.

766. Schwartz L, Morsi A. The draw-back stent deployment technique: a strategy for the treatment of coronary branch ostial lesions. *J Invasive Cardiol* 2002;14(2):66-71.

767. Szabo S, Abramowitz B, Vaitkus P. New technique of aorto-ostial stent placement. *Am J Cardiol* 2005;96:p212H.

768. Gutierrez-Chico JL, Villanueva-Benito I, Villanueva-Montoto L, et al. Szabo technique vs. conventional angiographic placement in bifurcations 010-001 of Medina and in aorto-ostial stenting: angiographic and procedural results. *EuroIntervention* 2010;5(7):801-8.

769. Park DW, Hong MK, Suh IW, et al. Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease. *Am J Cardiol* 2007;99(6):760-5.

770. Al-Lamee R, Ielasi A, Latib A, et al. Comparison of long-term clinical and angiographic outcomes following implantation of bare metal stents and drug-eluting stents in aorto-ostial lesions. *Am J Cardiol* 2011;108(8):1055-60.

771. Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. *J Am Coll Cardiol* 2004;44(5):967-71.

772. Lee SW, Kim SH, Kim SO, et al. Comparative long-term efficacy and safety of drug-eluting stent vs. coronary artery bypass grafting in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry. *Catheter Cardiovasc Interv* 2012;80(2):206-12.

773. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. *Eur Heart J* 2005;26:804-47.

774. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. *Eur Heart J* 2011;32(23):2922-32.

775. Patrono C, Rodriguez LA, Landolfi R, Baigent C. Low-Dose Aspirin for the Prevention of Atherothrombosis. *N Engl J Med*. 2005;353:2373-83.

776. Antiplatelet tc. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.

777. Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. *JAMA* 2012;308(23):2507-16.

778. Price MJ, Berger PB, Teirstein PS, et al. Standard vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011;305(11):1097-105.

779. Grines CL, Bonow RO, Casey DE Jr, et al. American Heart A, American College of C, Society for Cardiovascular A, Interventions, American College of S, American Dental A, American College of P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation* 2007;115:813-18.

780. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. *J Am Coll Cardiol* 2004;44(1):14-9.

781. Biondi-Zoccai G, Valgimigli M, Margheri M, et al. Assessing the role of eptifibatid in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. *Am Heart J* 2012;163(5):835.e1-e7.

782. Kastrati A, Mehilli J, Schuhlen H, et al. Intracoronary S, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. *N Engl J Med* 2004;350(3):232-8.

783. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. *JAMA* 2004;292(6):696-703.

784. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008;359(7):688-96.

785. Ndrepepa G, Schulz S, Keta D, et al. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. *Am J Cardiol* 2010;105(2):163-7.

786. Montalescot G, White HD, Gallo R, et al. Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention. *N Engl J Med* 2006;355(10):1006-17.

787. Montalescot G, Gallo R, White HD, et al. Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. *JACC Cardiovasc Interv* 2009;2(11):1083-91.

788. Silvain J, Beygui F, Barthelemy O, P et al. Efficacy and safety of enoxaparin vs. unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. *BMJ* 2012;344.

789. Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading vs. routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) randomized trial. *J Am Coll Cardiol* 2010;56(7):550-7.

790. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. *J Am Coll Cardiol* 2006;48(5):931-8. 791. Steinhilb SR, Berger S, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. *JAMA* 2002;288:2411-8.

792. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients. 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. *Eur Heart J* 2008;29(12):1495-503.

793. Collaborative overview of randomised trials of antiplatelet therapy: I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ (Clinical research ed.)* 1994;308(6921):81-106.

794. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009;373(9678):1849-60.

795. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 2000;102(6):624-9.

796. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. *Circulation* 2001;104(5):539-43.

797. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin vs. ticlopidine and aspirin after the placement of coronary-artery stents. *Circulation* 2000;101(6):590-3.

798. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900 mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. *Circulation* 2005;112(19):2946-50.

799. Valgimigli M, Campo G, Monti M, et al. Short- vs. long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 2012;125(16):2015-26.

800. Schömig A, Neumann FJ, Kastrati A, et al. Arandomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334(17):1084-9.

801. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339(23):1665-71.

802. Casseese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. *Eur Heart J* 2012;33(24):3078-87.

803. Gwon HC, Hahn JY, Park KW, et al. Six-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promis Vs. Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. *Circulation* 2012;125(3):505-13.

804. Feres F, Costa RA, Abizaid A, et al. Three vs. Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial. *JAMA* 2013;310(23):2510-22.

805. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet

- Therapy following Endeavor zotarolimus-eluting stent implantation). *J Am Coll Cardiol* 2012;60(15):1340–8.
806. Schulz S, Mehilli J, Neumann FJ, S et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. *Eur Heart J* 2010;31(20):2482–91.
807. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. *Arch Intern Med* 2007;167(22):2423–30.
808. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. *Eur Heart J* 2009;30:1457–66.
809. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation* 2009;119(14):1873–82.
810. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? *Circulation* 2009;119(21):2854–8.
811. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel vs. clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med* 2012;367(14):1297–309.
812. Mehta S, Tanguay JF, Eikelboom JW, et al. Double-dose vs. standard-dose clopidogrel and high-dose vs. low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet* 2010;376:1233–43.
813. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *Lancet* 2002;359(9302):189–98.
814. Kastrati A, Mehilli J, Neumann F-J, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. *JAMA* 2006;295(13):1531–38.
815. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med* 2006;355(21):2203–16.
816. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. *JAMA* 2007;298(21):2497–506.
817. Kastrati A, Neumann F-J, Schulz S et al. Abciximab and heparin vs. bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med* 2011;365(21):1980–9.
818. O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy safety of prasugrel with without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. *J Am Coll Cardiol* 2009;54(8):678–85.
819. Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin vs. unfractionated heparin in non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol* 2006;48(7):1346–54.
820. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292(1):45–54.
821. Kastrati A, Neumann F-J, Mehilli J, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008;359(7):688–96.
822. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med* 2006;354(14):1464–76.
823. Steg PG, James S, Harrington RA, et al. Ticagrelor Vs. Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. *Circulation* 2010;122(21): 2131–41.
824. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. *Circulation* 1999;100(15):1593–601.
825. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;358(9281):527–33.
826. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes. *N Engl J Med* 2013;369(11):999–1010.
827. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs. standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. *JAMA* 2010;304(12):1339–49.
828. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet* 2009;373(9665):723–31.
829. Erlinge D, Ten Berg J, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. *J Am Coll Cardiol* 2012;60(20):2032–40.
830. Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 inhibitors vs. clopidogrel in percutaneous coronary intervention: a meta-analysis. *J Am Coll Cardiol*. 2010;56(19):1542–51.
831. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. *Eur Heart J* 2009;30:2705–13.
832. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *N Engl J Med* 2001;344(25):1895–903.
833. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA* 2003;290(12):1593–9.
834. Herrmann HC, Lu J, Brodie BR, et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. *JACC Cardiovascular Interventions* 2009;2(10):917–24.
835. Van't Hof AW, Ten Berg J, Heestermans T, et al. Ongoing Tirofiban In Myocardial infarction Evaluation 2 study g. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. *Lancet* 2008;372(9638):537–46.
836. en Berg JM, van 't Hof AW, Dill T, et al. Effect of early, prehospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. *J Am Coll Cardiol* 2010;55(22):2446–55.
837. Montalescot G. Mechanical reperfusion: treat well, treat on time too. *Lancet* 2008; 372(9638):509–10.
838. Stone GW, Maehara A, Witzensbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. *JAMA* 2012;307(17):1817–26.
839. Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary vs. intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. *Lancet* 2012;379(9819):923–31.
840. Stone GW, Witzensbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med* 2008;358(21):2218–30.
841. Steg PG, van 't Hof AW, Hamm CW, et al. Bivalirudin Started during Emergency Transport for Primary PCI. *N Engl J Med* 2013;369(23):2207–17.
842. Shahzad A, Kemp I, Mars C, et al; for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomized controlled trial. *Lancet* 2014. doi: 10.1016/S0140-6736(14)60924-7.
843. Richardt G. Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. *Eur Heart J*. Published online 9 May 2014; doi: 10.1093/eurheartj/ehu182.
844. Collet J-P, Huber K, Cohen M, et al. A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial). *Am J Cardiol* 2013;112(9):1367–72.
845. Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA* 2006;295(13):1519–30.
846. Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. *Clin Res Cardiol* 2012;101(4):305–12.
847. Koul S, Smith JG, Schersten F, et al. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Eur Heart J* 2011;32(23):2989–97.
848. Dorler J, Edlinger M, Alber HF, et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. *Eur Heart J* 2011;32(23):2954–61.
849. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. *Journal of Thrombosis and Haemostasis: JTH* 2011;9(12):2361–70.
850. Montalescot G, Zeymer U, Silvain J, et al. Intravenous Enoxaparin or Unfractionated Heparin in Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. *Lancet* 2011;378(9792):693–703.
851. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). *J Am Coll Cardiol* 2003;42(7):1188–95.
852. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. *N Engl J Med* 2013;368(14):1303–13.
853. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. *Lancet* 2013;382(9919):1981–92.
854. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. *JAMA* 2012;307(3):265–74.

855. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med.* 2012;366:9–19.
856. Gibson CM, Chakraborti AK, Mega J, et al. Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. *J Am Coll Cardiol* 2013;62(4):286–90.
857. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). *J Am Coll Cardiol* 2013;61(18):1853–9.
858. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med.* 2011;365(8):699–708.
859. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J* 2011;32(22):2781–9.
860. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *Eur Heart J* 2011;32(20):2541–54.
861. Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation* 2009;119(22):2877–85.
862. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban vs. placebo in patients with acute coronary syndromes (ATLASACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet* 2009;374(9683):29–38.
863. Ruiz-Nodar JM, Mariñ F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. *J Am Coll Cardiol* 2008;51(8):818–25.
864. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Archives of Internal Medicine* 2010;170(16):1433–41.
865. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. *Circulation* 2012;126(10):1185–93.
866. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. *Circulation. Cardiovascular Interventions* 2011;4(5):522–34.
867. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary: a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2010;31(11):1311–8.
868. Saratoff N, Martischinig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. *J Am Coll Cardiol* 2013;61(20):2060–6.
869. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. *Circulation* 2012;125(23):2873–91.
870. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013;381(9872):1107–15.
871. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *N Engl J Med* 2010;362(15): 1374–82.
872. Kedhi E, Stone GW, Kereiakes DJ, et al. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. *EuroIntervention* 2012;8(5):599–606.
873. Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. *Eur Heart J* 2014, published online February 7.
874. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. *Eur Heart J* 2013;34(23):1708–13, 1713a–3b.
875. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA* 2005;294(24):3108–16.
876. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. *Eur Heart J.* 2011;32(15):1854–64.
877. James S, Budaj A, Aylward P, et al. Ticagrelor vs. clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation* 2010;122(11):1056–67.
878. Sousa-Uva M, Storey R, Huber K, et al. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. *Eur Heart J* 2014;35:1510–14.
879. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. *The Annals of Thoracic Surgery* 2012;94(5):1761–1781.
880. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. *J Am Coll Cardiol* 2012;60(5):388–396.
881. Varenhorst C, Alström U, Scirica BM, HogueCWA, senblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. *J Am Coll Cardiol* 2012;60(17):1623–30.
882. Kwak Y-L, Kim J-C, Choi Y-S, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. *J Am Coll Cardiol* 2010;56(24):1994–2002.
883. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. *Circulation. Cardiovascular interventions* 2012;5(2):261–9.
884. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. *British Journal of Anaesthesia* 2010;104(3):285–91.
885. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. *Int J Cardiol* 2000;76(2–3):257–8.
886. Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. *Journal of Cardiac Surgery* 2013;28(2):109–16.
887. Stone GW, Witzencbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet* 2013;382(9892):614–23.
888. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. *JAMA* 2011;306(11):1215–23.
889. Breet NJ, vanWerkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation (POPular Study). *JAMA* 2010;303(8):754–62.
890. Aradi D, Storey RF, Komocsi A, et al, on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J* 2014;35(4):209–15.
891. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of Prasugrel Vs. Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. *J Am Coll Cardiol* 2012;59(24):2159–64.
892. Collet J-P, Cuisset T, Range G, et al. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. *N Engl J Med* 2012;367(22):2100–9.
893. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P4502C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet* 2009;373(9660):309–17.
894. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. *Lancet* 2010;376(9749):1312–9.
895. Mega JL, Simon T, Anderson JL, et al. CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis. *Circulation* 2009;120:S598-b-9.
896. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P4502C19 polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. *J Am Coll Cardiol.* 2008;51:1925–34.
897. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial: the RAPID GENE trial. *Lancet* 2012 ([http://dx.doi.org/10.1016/S0140-6736\(12\)60161-5](http://dx.doi.org/10.1016/S0140-6736(12)60161-5)).
898. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. *Am J Cardiol* 2005;95(4):509–10.
899. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996;348(9038):1329–39.
900. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 2010;363(20):1909–17.
901. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. *Lancet* 2009;374(9694):989–97.

902. Birkmeyer JD, Finlayson EV, Birkmeyer CM. Volume standards for high-risk surgical procedures: potential benefits of the Leapfrog initiative. *Surgery* 2001;130(3):415–22.
903. Post PN, Kuijpers M, Ebels T, Zijlstra F. The relation between volume and outcome of coronary interventions: a systematic review and meta-analysis. *Eur Heart J* 2010;31(16):1985–92.
904. Jones DA, Gallagher S, Rathod K, et al. Clinical outcomes after myocardial revascularization according to operator training status: cohort study of 22 697 patients undergoing percutaneous coronary intervention or coronary artery bypass graft surgery. *Eur Heart J* 2013;34(37):2887–95.
905. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. *N Engl J Med* 2003;349(22):2117–27.
906. Puskas JD, Mack MJ, Smith CR. On-pump vs. off-pump CABG. *N Engl J Med* 2010;362(9):v851; author reply 853–4.
907. Wijns W, Kolh PH. Experience with revascularization procedures does matter: low volume means worse outcome. *Eur Heart J* 2010;31(16):1954–7.
908. Zacharias A, Schwann TA, Riordan CJ, et al. Is hospital procedure volume a reliable marker of quality for coronary artery bypass surgery? A comparison of risk and propensity adjusted operative and midterm outcomes. *Ann Thorac Surg* 2005;79(6):1961–9.
909. Kurlansky PA, Argenziano M, Dunton R, et al. Quality, not volume, determines outcome of coronary artery bypass surgery in a university-based community hospital network. *J Thorac Cardiovasc Surg* 2012;143(2):287–93.
910. Auerbach AD, Hilton JF, Maselli J, et al. Shop for quality or volume? Volume, quality, and outcomes of coronary artery bypass surgery. *Ann Intern Med* 2009;150(10):696–704.
911. Hannan EL, Wu C, Walford G, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. *Circulation* 2005;112(8):1171–9.
912. McGrath PD, Wennberg DE, Dickens JD Jr, et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. *JAMA* 2000;284(24):3139–44.
913. Nallamothu BK, Wang Y, Magid DJ, et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. *Circulation* 2006;113(2):222–9.
914. Spaulding C, Morice MC, Lancelin B, et al. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. *Eur Heart J* 2006;27(9):1054–60.
915. Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. *Circulation* 2001;104(18):2171–6.
916. Ho V. Evolution of the volume-outcome relation for hospitals performing coronary angioplasty. *Circulation* 2000;101(15):1806–11.
917. Kastrati A, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. *J Am Coll Cardiol* 1998;32(4):970–6.
918. Canto JG, Every NR, Magid DJ, et al. The volume of primary angioplasty procedures survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. *N Engl J Med* 2000;342(21):1573–80.
919. Zahn R, Gottwik M, Hochadel M, et al. Volume-outcome relation for contemporary percutaneous coronary interventions (PCI) in daily clinical practice: is it limited to high-risk patients? Results from the Registry of Percutaneous Coronary Interventions of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Heart* 2008;94(3):329–35.
920. Khattab AA, Hamm CW, Senges J, et al. Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry. *Circulation* 2009;120(7):600–6.
921. Kumbhani DJ, Cannon CP, Fonarow GC, et al. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. *JAMA* 2009;302(20):2207–13.
922. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;58(24):e44–e122.
923. Di Mario C, Di Sciascio G, Dubois-Randé JL, et al. Curriculum and syllabus for Interventional Cardiology subspecialty training in Europe. *EuroIntervention* 2006;2(1):31–6.
924. Hlatky MA, Boothroyd DB, Reitz BA, et al. Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among medicare beneficiaries. *J Am Coll Cardiol* 2014;63(1):33–9.
925. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2012;33(13):1635–701.
926. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376(9753):1670–81.
927. Cannon CP, Braunwald E, McCabe CH, et al. Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350(15):1495–504.
928. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352(14):1425–35.
929. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992;327(10):669–77.
930. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991;325(5):293–302.
931. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349(20):1893–906.
932. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;362(9386):772–6.
933. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008;358(15):1547–59.
934. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342(3):145–53.
935. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003;362(9386):782–88.
936. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA* 2003;290(1):86–97.
937. Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. *Circulation* 2005;112(6):924–34.
938. Taylor RS, Brown A, Abraham S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med* 2004;116(10):682–92.
939. Taylor RS, Unal B, Critchley JA, Capewell S. Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements? *Eur J Cardiovasc Prev Rehabil* 2006;13(3):369–74.
940. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. *Circulation* 2010;121(1):63–70.
941. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. *Ann Intern Med* 2005;143(9):659–72.
942. Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev* 2011(7):CD001800.
943. Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* 2013;20(4):620–40.
944. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target, 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. *Eur Heart J* 2011;32(12):1500–8.
945. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet* 2004;364(9437):849–57.
946. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. *J Hypertens* 2009;27(5):923–34.
947. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998;351(9118):1755–62.
948. Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography. *Ann Intern Med* 1998;128(12 Pt 1):965–74.
949. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 1993;329(14):977–86.
950. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352(9131):837–53.
951. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353(9146):9–13.
952. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344(22):1651–8.
953. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;353(9169):2001–7.

954. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26(3):215–25.
955. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999; 341(10):709–17.
956. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;364(1):11–21.
957. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; 348(14):1309–21.
958. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. *Lancet* 2010;376(9744):875–85.
959. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with leftventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. *Eur Heart J* 2013;34(29):2263–70.
960. Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. *Eur Heart J* 2014;35:2021–31.
961. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary intervention (BIOSCIENCE): a randomised, single-blind, noninferiority trial. *Lancet* 2014. doi 10.1016/S0140-6736(14)61038-2.